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1. Introduction 
 
1.1 Histamine 
 Histamine is a low molecular mass biogenic amine found in many animal 
tissues with a wide spectrum of physiological as well as pathological effects. Its effect 
is mediated by four receptors variably expressed in various tissues with different 
functions. This made histamine one of the most intensively studied molecules in 
medicine [1].   
 
1.1.1. History 
 Almost a hundred years ago histamine or 2-(1-h-imidazo-4-lyl)ethylamine was 
discovered by Sir Dale from the mould ergot, which was later characterized as a 
smooth muscle stimulator in gut and respiratory tract, as well as vasodepressor. 
Histamine was then isolated from liver and lung, and was found to be a natural 
constituent of the body with a physiological role. Further investigation reported that 
histamine injection in animals leads to a shock-like syndrome which identified 
histamine as a mediator of anaphylactic reactions in 1932 [2;3].  
  
1.1.2. Histamine synthesis and storage 
 Histamine is synthesized from the amino acid L-histidine by L-histidine 
decarboxylase (HDC). Histamine production was detected in various cells like central 
nervous system (CNS) neurons and gastric mucosa parietal cells, but the main 
sources of histamine are the immune cells including eosinophils, basophils, and mast 
cells. In these cells histamine is stored intracellularly in vesicles and released upon 
stimulation. Remarkably, other immune cells also show high HDC activity and are 
capable to produce large amounts of histamine. These cells include 
monocytes/macrophages, dendritic cells (DC), neutrophils and T and B cells [4;5]. 
1. Introduction 
 
 
2 
These cells do not store histamine, and therefore, it is released as soon as it is 
synthesized [6]. HDC activity is easily modulated both in vitro, in response to 
cytokines such as IL-3, GM-CSF, IL-1, IL-18, IL-12, M-CSF and TNF, and in vivo, 
during allograft rejection, infection, inflammation and stimulation with LPS.  
 
1.1.3. Histamine metabolism 
 Histamine can be metabolized by two pathways: oxidation or methylation. The 
oxidation pathway by diamine oxidase (DAO) is mainly responsible for extracellular 
histamine degradation. This includes histamine released upon stimulation and 
histamine-rich food ingestion [7;8], because DAO is stored in plasma membrane–
associated vesicular structures in epithelial cells. Conversely, the histamine 
methylation pathway by histamine-N-methyltransferase (HNMT) is capable of 
degrading histamine only in the intracellular space of cells, because of the cytosolic 
localization of HMNT [9]. HNMT is considered the key enzyme for histamine 
degradation in the bronchial epithelium as well as some other tissues, based on its 
wide expression in human tissues [10;11]. In contrast, DAO expression is restricted 
to specific tissues like small bowel, colon ascendens, placenta and kidney [12].  
 
1.1.4. Histamine receptors  
 Four histamine receptors (HRs) that belong to the G-protein-coupled receptor 
(GPCR) family mediate the wide variety of histamine effects.  
 The histamine H1 receptor (H1R) is responsible for most of the acute allergic 
responses. Based on that, several drugs were designed to antagonize the histamine 
effect, and the term “anti-histamines” was used to describe the anti-H1R effect. 
Among a long list of H1R antagonists, diphenhydramine and cetirizine as H1R inverse 
agonists are effective in the allergic inflammatory treatment.  
 The histamine H2 receptor (H2R) is mainly known for its role as a modulator of 
gastric acid secretion, and its antagonists such as famotidine and ranitidine are 
successfully used for the treatment of peptic ulcer, and gastroesophageal reflux 
disease.  
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 The histamine H3 receptor (H3R) is highly expressed in the nervous system 
and modulates the neurotransmitter levels. Antagonists for H3R are still under 
development, where its potential use is in sleep and cognition disorder treatment.  
 In contrast to H1R and H2R, H4R has a more selective expression pattern, 
being expressed mainly in cells of haematopoietic origin, in particular DC, mast cells, 
eosinophils, monocytes, basophils and T cells, giving rise to an immune modulatory 
role. H4R is encoded by a gene containing three exons separated by two large 
introns. The sequence homology between human and mouse receptor is 68% with 
390 and 391 amino acids, respectively. A considerable sequence homology is also 
observed in different species between H4R and H3R which is 34-35%. Therefore, 
many H3R ligands like clobenpropit and thioperamide bind to H4R as an agonist and 
antagonist, respectively [13-16]. The affinity of histamine binding to different HRs 
varies significantly, with Ki values ranging from 5-10 nM for H3R and H4R, to 2-10 µM 
for H1R and H2R [17;18]. 4-Methyl histamine (4MEH) was considered as a human 
H2R agonist, but the discovery of H4R revealed that it possesses a 100-fold higher 
selectivity for human H4R than human H2R. Some other data show similar results for 
the mouse H4R in vitro as well as in vivo [19;20]. In 2004 Thurmond et al. reported 
the first H4R selective antagonist with anti-inflammatory effect, 1-(5-chloro-1H-indol-
2-yl)carbonyl-4-methylpiperazine or JNJ 7777120. JNJ 7777120 was repeatedly used 
since then by several groups to antagonize H4R in human, mouse and rats [18;21-
23]. Therefore, 4MEH and JNJ 7777120 were used in the following experiments as 
selective agonist and antagonist in mouse cells. Recently, and based on the frequent 
reports about the immunological role of H4R, an increasing number of reports 
appeared with the focus on the specific effect of H4R on the immune system. This 
was associated with numerous agonists and antagonists designed by several 
research groups and pharmaceutical companies [24-32].   
 
1.1.4.1. Histamine receptor-mediated signalling 
 HRs are coupled to different Gα subunits as intracellular mediators. Histamine 
binding to H1R generates an intracellular signal through Gαq, which leads to allergy 
symptoms in the skin, nose and airway. This is associated with phospholipase C 
activation, inositol phosphate production and Ca2+ influx as well as activation of the 
transcription factor NFκB. H2R signaling leads to Gαs activation, which activates 
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adenylate cyclase and increases the intracellular cAMP levels. H3R and H4R signals 
are mediated by Gαi/o proteins, leading to activation of mitogen-activated protein 
kinases (MAPKs) and inhibition of cAMP formation, as well as modulation of ion 
channels and increases Ca2+ influx. In addition H4R activation also leads to activation 
of the transcription factor AP-1 [1;33;34].  
 
1.1.4.2. Histamine receptors constitutive activity  
 The expression of GPCR in a recombinant system revealed a constitutive 
spontaneous receptor activity, which occurred in the absence of an agonist. This 
basal activity can be modulated upon binding of an agonist or an inverse agonist to 
the receptor. The two state model hypothesis assumes that GPCR isomerize from an 
inactive (R) state to an active (R*) state [35]. Agonist binding to the receptor 
increases the basal activity and maximally stabilizes the R* state which can couple 
to, and activate, G-proteins, by promoting the GDP/GTP exchange at G-proteins. 
Conversely, binding of an inverse agonist to the receptor decreases the basal activity 
and maximally stabilizes the R state, where GPCR are uncoupled from G-proteins. 
Antagonists can bind to both states with the same affinity without altering the 
equilibrium between R and R* or the basal activity, but they block both the inhibitory 
effects of inverse agonists and the stimulatory effects of agonists (Fig. 1.1) 
[21;35;36].   
 Like other GPCR, constitutive activity has been observed in all human 
histamine receptors [21;28;37-39]. This phenomenon is most commonly seen in 
systems with a high expression level of the receptor [40-42].      
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Fig. 1.1: Two-state model of GPCR activation. A: The agonist binding to the receptor leads to the 
active state of the receptor (R*), which promotes the GDP/GTP exchange at G-proteins and mediates 
the intracellular signal. Na+ acts as an allosteric inverse agonist which stabilizes the inactive state (R) 
and reduces the basal G-protein activity. B: Partial agonists and partial inverse agonists have lower 
efficacies than full agonists and full inverse agonists, respectively. Adapted from Seifert et al.[35] 
 
1.2. The role of histamine in the immune system 
 The effect of histamine as immune modulator has been reported frequently 
[5;43-45]. However, the co-expression of HRs on the same cell types, and the 
histamine concentrations used to mimic the in vivo conditions, complicate the 
recognition of the specific role of each receptor [33;46]. It has been long recognized 
that the interaction of histamine with H1R mediates an allergic effect with additional 
immune and inflammatory functions. However, the discovery of H4R and its functions 
revealed that there is an overlap in the histamine effect through H1R and H4R [34].  
   
1. Introduction 
 
 
6 
1.2.1 The role of histamine in monocytes and macrophages  
 Several reports have examined the expression of HRs in monocytes and 
macrophages in different species. The expression of H1R is up-regulated during the 
differentiation of human monocytes to macrophages in vitro [47], whereas 
inflammatory stimuli such as IFN-γ alone or with TNF up-regulate H4R in human 
monocyte [48]. In the same report, Dijkstra et al. state that H4R stimulation induces 
Ca2+ influx and inhibits the production of CCL2 (monocytes chemoattractant protein 1 
or MCP1). The functional expression of H4R in human monocytes was also reported 
in THP-1 clone 15 by Damaj et al. in 2007. These cells exhibit a chemotactic 
response towards histamine, this response is inhibited by thioperamide, but not with 
diphenhydramine (H1R antagonist) nor cimetidine (H2R antagonist) [49]. Histamine 
effect through H2R inhibits TNF, IL-12 and IL-18 production from LPS-activated 
human monocytes. It can also down-regulate CD14 expression on human monocytes 
[50]. There is one report on the role of H1R in human lung macrophage activation 
which leads to IL-6 and β-glucuronidase production within 2-6 hours. Notably, no 
other confirmation of the role of histamine in macrophage activation has been 
reported [50-57]. In a single report about rat peritoneal macrophages, histamine was 
claimed to inhibit chemotaxis, phagocytosis, superoxide anion production, and the 
production of TNF and IL-12 [58].  
 HDC activity and histamine production was also reported in human precursor 
macrophages and macrophages. Furthermore, macrophages and precursor 
macrophages generate histamine upon exposure to LPS and IL-1 or M-CSF, 
respectively [59]. HDC activity is also induced in mouse macrophages after Yersinia 
enterocolitica infection, and the treatment of infected mice with the H2R agonist 
dimaprit increased mice survival [60]. Another report relating histamine to 
macrophage function revealed that macrophages migrated in the human 
atherosclerosis lesion express HDC, and the regional histamine derived from 
macrophages may be relatively low in concentration but longer lasting in duration 
[61;62].    
 
1.2.2. The role of histamine in DC 
 The expression profile of HRs on DC reveals co-expression of H1R, H2R and 
H4R [34;49]. In other reports, H3R in addition to H4R expression has been observed 
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in human and mouse immature DC [63-65]. Histamine induces chemotaxis in human 
DC mainly through H4R and H1R [66]. IL-12p70 production from human DC can be 
also inhibited by histamine through H4R [64]. In addition, cytokine production can also 
be modulated by histamine, this includes induction of IL-6 and IL-10 production. The 
inhibition of IL-12 and the induction of IL-6 and IL-10 from DC can drive T-helper 2 
(TH2) cell polarization in human and mouse cells by H1R and H4R [64;67].  
 
1.2.3. The role of histamine in T-lymphocytes 
 The role of histamine in driving the immune response in towards TH1 (anti-
microbial and cellular immunity) and TH2 (allergic response) has been intensively 
investigated. In the last 20 years, several reports of histamine effects on the 
production of IFN-γ, IL-4 and IL-13 have been published. These cytokines are 
essential in driving the naïve T cell differentiation into TH1 or TH2 [68]. In a recent 
report, functional expression of H4R in human TH2 cells as well as TH1 cells was 
reported, in which H4R stimulation increases IL-31 production in TH2 cells. The role of 
IL-31 is associated with inflammatory bowel disease and airway hypersensitivity [23].  
 The expression of H4R in CD4+ T cells and CD8+ T cells has been shown in 
human cells but not in the mouse. However, there is considerable evidence that 
histamine can act on mouse CD4+ T cells, and regulate the immune response in 
asthma model through H4R [69;70]. Histamine can also induce a chemotactic effect 
in human T cells in vitro, with evidence of H1R and H4R involvement [71;72].   
 
1.2.4. The role of histamine in mast cells 
 Previously, H4R was considered to be exclusively expressed in mast cells and 
eosinophils in addition to H1R and H2R. Furthermore, the histamine effect through 
H4R was reported to induce chemotaxis in mouse mast cells. In response to 
histamine, there was redistribution of mast cells to the tracheal epithelium that could 
be blocked by systemic administration of the H4R antagonist. This change in tissue 
localization of mast cells in vivo may mimic what happens in allergic conditions, 
where the presence of allergens in the airways leads to release of histamine either by 
the resident mast cells or by other cells [18;18;73].  
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1.2.5. The role of histamine in eosinophils 
 The chemotactic role of H4R in human eosinophils was the first function 
assigned to H4R. Histamine at low concentrations can induce chemotaxis in human 
eosinophils through H4R, but at higher concentrations, chemotaxis is inhibited via 
H2R activation [74-78].      
 
1.3. The role of H4R in the development of several pathological 
mechanisms 
1.3.1. Asthma 
 The expression of H4R in most of the immune cells contributing to the asthma 
inflammation mechanism, and the early observation about the anti-inflammatory role 
of H4R antagonist suggest that this receptor may play a role in asthma development. 
In addition, the histamine contribution in driving the asthmatic response, and the 
limited effect of the traditional H1R antagonist in asthma treatment, increase the 
evidence of possible role of H4R in the development and treatment of the disease 
[34].  
 In the mouse asthma model, H4R-deficient mice (H4R -/-) or those given H4R 
antagonists during sensitization, show reduced lung inflammation and TH2 
inflammatory cytokines [69]. The effect was similar in mast cell-deficient mice, 
suggesting that mast cells were not the main source of histamine, and histamine 
produced by DC and other leukocytes can stimulate H4R and induce inflammation. 
The preventive effect of JNJ 7777120 in asthma reaction was confirmed in a guinea 
pig model [79].  
 
1.3.2. Pruritus  
 Histamine is an important mediator of itching in the periphery, and might also 
function as a transmitter of pruritic signals in the CNS. In the mouse model, H1R -/- 
mice and mice treated with H1R antagonists show a partial inhibition of itching 
induced by mast cells degranulation with compound 48/80. A similar effect was also 
found in an IgE-mediated-mast-cell activation model. In H4R -/- mice as well as in 
mice treated with JNJ 7777120 the itching behaviour was notably diminished, 
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suggesting that a combination between H1R and H4R antagonists could completely 
eliminate histamine-induced itching [80]. Blocking H4R with JNJ 7777120 has a 
remarkable effect on reducing the itch in allergic contact dermatitis in mice [81]. 
 
1.3.3. Other pathological mechanisms 
 The role of H4R was investigated in several animal models by examining the 
effect of JNJ 7777120 in these models. In a rat model, JNJ 7777120 shows a 
promising effect in treating experimental colitis induced by trinitrobenzene sulphonic 
acid (TNBS) [22]. A similar effect was observed in treating rats with carrageenan-
induced inflammation [82]. JNJ 7777120 also reduced the nasal symptoms in mice 
with allergic rhinitis [83]. Furthermore, the investigation of an allergic conjunctivitis 
model in the mouse, revealed that JNJ 7777120 can inhibit eye scratching behaviour 
induced by histamine and 4MEH, and the combination with levocabastine (H1R 
antagonist) could inhibit both eye scratching and the allergic-like symptoms score 
[84].  
 
1.4. Macrophages 
1.4.1. Historical background 
 Macrophages are the first cells to be assigned a function in host defence. 
They were first recognized by their size and phagocytic properties. 100 years ago 
Elie Metchnikoff had discovered the phagocytic activity protecting the host from 
infection through a process he called ‘innate immunity’. This was awarded with the 
Nobel Price in Physiology and Medicine in 1908, simultaneously to Paul Ehrlich who 
in contrast described what is now called ‘adaptive immunity’. Macrophages remain a 
hot topic in immunity based on their dual role in innate and adaptive immunity [85].  
 
1.4.2. Monocyte-derived macrophages in tissues 
 Macrophages are present in virtually all tissues. They differentiate from 
circulating peripheral blood monocytes, which migrate into tissue in the steady state 
or in response to inflammation. In humans, monocyte development starts from a 
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common myeloid progenitor cell in the bone marrow that is the precursor of many 
other immune cells including neutrophils, eosinophils, basophils, macrophages, DC 
and mast cells [86]. During monocyte development, myeloid progenitor cells or 
granulocyte/macrophage colony-forming units (GM-CFU) sequentially give rise to 
monoblasts, pro-monocytes and finally monocytes, which proceed to the 
bloodstream. Once monocytes migrate and settle in tissues, they mature and 
become macrophages which exist in all organs and connective tissues, and have 
been given special names to designate a specific location (Fig. 1.2). Each type of 
those macrophages plays a key role in the homeostasis and immune reaction in their 
organs, and initiates the immune response at all sites where microbes may exist.  
 Mouse monocytes in general have different cell-surface markers than human 
monocytes. This seems to give rise to distinct physiology between human and mouse 
[86-90].       
 
 
 
Fig. 1.2: Monocytes differentiation from bone marrow and tissue-specific-macrophages. Adapted from 
Mosser et al. [91]   
 
 Human macrophages are obtained in vitro by incubating isolated blood 
monocytes with macrophages-colony stimulating factor (M-CSF) for 4 days [92;93]. In 
contrast, in mouse and due to the low number of circulating monocytes, macrophage 
differentiation starts from bone marrow cells to generate bone marrow-derived 
macrophages (BMDM) [93]. BMDM represent a suitable cell model to generate non-
activated macrophages in vitro that mimic the tissue-residing macrophages in their 
cell-surface markers and functions [94].  
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1.4.3. Recognition of microbes by macrophages  
 Macrophages express surface receptors that recognize microbes and 
stimulate phagocytosis and killing mechanisms. These receptors can detect the 
danger signals that are present in the debris of necrotic cells, injury or infection. 
Specifically, these receptors are capable of recognizing ‘pathogen associated 
molecular patterns’ (PAMPs) that exist in the targets. Among these receptors, the 
Toll-like receptors (TLRs) represent one of the main receptors required for 
macrophage functions. The intracellular signal of these TLR goes through an adaptor 
molecule called molecule myeloid differentiation primary-response gene 88 (MyD88). 
The best example of the TLR response in macrophages is lipopolysaccharide (LPS) 
recognition by TLR4, which leads to distinct macrophage activation. Macrophages 
also respond to signals produced by immune cells, which may activate them. In 
addition macrophages also produce several factors that influence their own 
physiology [91;95-97]. 
 
1.4.4. Macrophage activation 
 The term “activated macrophages” was used previously to describe 
inflammatory macrophages which phagocytose and kill microorganisms. Thereafter, 
this term defined a heterogeneous group of cells derived from different activation 
conditions with different physiology and immune functions (Fig. 1.3). 
 
1.4.4.1. Classically activated macrophages 
 Classically activated macrophages are also known as M1 macrophages. The 
classical activation mechanism was the first discovered mechanism of macrophage 
activation. Two signals mediate the activation; Interferon-γ (IFN-γ) and tumor-
necrosis factor (TNF) resulted in macrophages that had enhanced microbicidal or 
tumoricidal capacity and secreted high levels of pro-inflammatory cytokines and 
mediators. IFN-γ can be produced by innate or adaptive immune cells including 
natural killer (NK) cells and TH1 cells [98]. TNF is the second stimulus required for the 
classical activation. Its production is induced by TLR ligands from antigen-presenting 
cells as well as macrophages. This cooperates with IFN-γ and leads to an 
exogenous/autocrine manner of macrophage activation. Therefore, the term of 
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classicaly activated macrophages includes the IFN-γ- and LPS-activated cells. 
Macrophages can also be activated by direct TLR stimuli (e.g. LPS, CpG, flagellin) or 
by stimulating nucleotide oligomerization domain (NOD) receptors. This activation 
phenotype resembles to a certain extent the classical activation, especially in the 
rapid TNF production. 
 The classically activated macrophages are mainly involved in host defence to 
bacterial infections and intracellular pathogens. This effect is mediated by several 
pro-inflammatory cytokines; for example, IL-1, IL-6, TNF and nitric oxide (NO), that 
are produced by classically activated macrophages. However, these macrophages 
with their killing capability can cause extensive damage to the host. Therefore their 
activation must be tightly controlled [86;99;100]. 
 
1.4.4.2. Wound-healing macrophages 
 Wound-healing macrophages were previously called alternatively activated 
macrophages or M2 macrophages. The name alternative implies that this is the only 
other (alternative) way that macrophages can be activated, and this is certainly not 
the case. The activation is mediated by IL-4 or IL-13, in which basophils and mast 
cells as well as other granulocytes are important sources of innate IL-4 production. In 
addition to injury, these cells can also produce IL-4 in response to chitin, a structural 
biopolymer that is found in some fungi and parasites. IL-4 stimulates arginase activity 
in macrophages, allowing them to convert arginine to ornithine, a precursor of 
polyamines and collagen, thereby contributing to the production of the extracellular 
matrix. Their primary function seems to be related to wound healing [91;101;102].  
 
1.4.4.3. Regulatory macrophages 
 Recently, the regulatory macrophage population was identified as a distinct 
population generated in response to both innate and adaptive immunity. The primary 
role of regulatory macrophages is to dampen the immune response and limit 
inflammation. Regulatory T cells (T-reg) can drive regulatory macrophage 
differentiation by IL-10 production. Moreover, the production of the anti-inflammatory 
cytokine Transforming growth factor-beta (TGF-β) by macrophages following the 
phagocytosis of apoptotic cells in the presence of pro-inflammatory stimuli can also 
contribute to the immunoregulatory function of these macrophages [103-105]. Other 
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inducers of regulatory macrophages are ligands of GPCRs including histamine and 
adenosine [106;107]. The exact mechanisms mediating the switch to regulatory 
functions remains unknown with some evidence for MAPK extracellular-signal-
regulated kinase (ERK) involvement [106;108]. 
 
 
            Mosser et al; Nat. Rev. Immunol. (2008) 
 
 
Fig. 1.3: The different population of activated macrophages. Adapted from Mosser et al. [91]   
 
1.4.5. Macrophage phagocytosis mechanism 
 Macrophages have the ability to clear infectious agents and apoptotic cells by 
phagocytosis, in which the discrimination between self and non-self is a key factor. 
The specificity of the phagocytic activity is achieved by a restricted number of 
phagocytosis receptors. This multi-step mechanism is initiated by particle recognition, 
which is mediated by a wide variety of surface receptors that bind directly or indirectly 
through opsonins (complement fragments, IgG) to the particle. FcγR is an example of 
phagocytosis receptors that require IgG opsonization to initiate phagocytosis. CD44 
can also internalize hyaluronan-coated particles in mouse macrophages in a process 
that involves complement receptor 3 (CR3).     
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 The phagocytosis mechanisms vary depending on the phagocytosed 
elements. Therefore, there is no single pathway by which phagocytosed elements 
can be internalized, but the recognition of PAMPs remains as a common initiator of 
the process. These PAMPs include mannans in the yeast cell wall, formylated 
peptides in bacteria, and LPS and lipoteichoic acids on the surface of Gram negative 
and Gram positive bacteria. Several receptors can recognize PAMPs such as 
integrins (CD11b/CD18), mannose receptors and scavenger receptors. In addition, 
many of the phagocytic receptors have dual functions, often mediating both adhesion 
and particle internalization. 
 In general, the uptake of large particles occurs by an actin-dependent 
mechanism, including rearrangements in the actin cytoskeleton that lead to the 
formation of the phagocytic cup. Once the phagocytic cup is closed the maturation 
process begins and phagosomes become increasingly more acidic and hydrolytically 
active. They transiently fuse with the recycling endosomal system, the secretory 
system (including secretory lysosomes), multi-vesicular bodies such as the MHC 
class II compartment and even the endoplasmic reticulum (Fig. 1.4) [95;109-114].  
 
 
 
Fig. 1.4: Phagocytic cup formation and phagosome maturation. Following engagement of 
phagocytic receptors, an area of the cell surface is remodelled around the particle, forming the 
phagocytic cup. Finally, the phagosome fuses with pre-existing, dense lysosomal bodies and 
equilibrates to a pH of 4.5–5.0. Adapted from Russell et al. [112] 
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1.4.6. Chemotaxis mechanism 
 Chemotaxis is the function in which the cells sense a chemical compound 
(chemoattractant) and migrate towards its higher concentration. It is an essential 
process in embryogenesis, angiogenesis, metastasis, and the immune response. 
Immune cells chemotaxis is considered as one of the essential properties of the cells 
to defend against pathogens and to migrate into tissues and ensure the cell to cell 
interactions [115;116].  
 In general, eukaryotic cells detect these chemical signals through GPCRs, 
which activate the chemotaxis mechanism only in the continuous presence of the 
external signal gradient [117]. It has previously been shown that Gαi signaling is 
generally important for cell migration, and pertussis toxin (PTX) from Bordetella 
pertussis, a specific inhibitor for the Gαi unit, completely blocks cell migration induced 
by most chemokines. Interestingly, Gαi itself does not seem to be required for cell 
migration. Instead, the free Gβγ subunit released from the Gi complex is necessary for 
the transduction of migratory signals [118-120]. The downstream signal of the GPCR-
mediated chemotaxis in neutrophils goes to the phosphatidylinositol-3-OH kinase 
(PI3K) phosphatase and tensin homolog (PTEN) pathway, and the p38 mitogen-
activated protein kinase pathway, with the p38 pathway dominating over the PI3K 
pathway [121].    
 
1.5. Dendritic cells (DC) 
 DC are potent antigen presenting cells (APCs) that possess the ability to 
uptake, transport, process and present antigens to naïve T cells and activate them. 
This step is the initiator of the adaptive immune response. DC are widely distributed 
in all tissues, especially in those that provide an environmental interface [122].  
 
 
1.5.1. The development of DC 
 It is important to mention that DC are not a single cell type, but a 
heterogeneous collection of cells, each cell type develops from unique progenitors. 
The development is driven by cytokine combinations, and the developed cells within 
a particular pathway exhibit distinct specialized functions [123]. Human and mouse 
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monocytes can undergo several differentiation steps and generate DC residing in the 
tissues. Myeloid DC are another mouse DC subtype differentiated from bone marrow 
cells. The cells are differentiated from bone marrow cells in the presence of 
granulocyte macrophages-colony stimulating factor (GM-CSF) for 8 days. The 
resulting cells are immature DC which express CD11c as a specific marker for mouse 
DC. The immature DC can be driven into maturation state by stimulation with antigen 
or TLR ligands such as LPS or CpG, this leads to mature DC which expresses CD80, 
CD86 and MHC class II [90;124;125]. 
 
1.6. Leishmania major (L. major)   
 L. major is a one of 15 different species of the protozoan parasite genus 
Leishmania, responsible for the human disease Leishmaniasis. Leishmaniasis 
severity ranges from self-limiting cutaneous infections to disseminating diffuse 
cutaneous, mucocutaneous and visceral Leishmaniasis. The infection affects more 
than 20 million people worldwide. Furthermore, the absence of vaccination and 
effective treatment, in addition to the co-infection with HIV, made Leishmaniasis as 
complex disease [126].  
 
1.6.1. Pathopysiology    
 L. major exists in two morphological forms, Promastigotes, amastigotes as an 
extracelluar and intracellular forms respectively. Promastigotes can subcutaneously 
infect the host by the bite of an infected sandfly. Leishmania are obligate intracellular 
pathogens, preferring phagocytes as host cells. Neutrophils are the first phagocytic 
cells that infiltrate to the subcutaneous site of infection. Upon phagocytosis, 
neutrophils serve as intermediate host cells, where L. major remain in the 
promastigote stage without multiplication. In the mean time neutrophils produce IL-8 
which attracts macrophages to the infected region. Subsequently, and because of the 
short lifespan of neutrophils, promastigotes use apoptotic neutrophils as a Trojan 
horse to infect their final host, the macrophages [127]. In the macrophages, the 
parasites loose their flagella and become amastigotes, where they survive and 
multiply by inhibiting the antimicrobial defense by several mechanisms [127;128].   
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1.6.2. The experimental model of Leishmaniasis in the mouse 
 Infecting mice with L. major comprises a valuable tool on the way to 
understand the cell-mediated response to intracellular pathogens. One of the early 
benefits of this model, is the observation that TH1 immune response is a key factor in 
controlling the parasite replication. This includes the generation of IFN-γ activated 
macrophages that are able to release nitric oxide (NO) and kill the parasites. 
Interestingly, Leishmaniasis prognosis varies basically in between the mouse strains. 
Leishmaniasis development in C57BL/6 is limited to local subcutaneous 
inflammation; and the mice survive and heal after a few weeks, because of their 
capability of generating a TH1 responses, whereas the TH2 immune responses 
associated with BALB/c mice make Leishmaniasis infection a lethal disease for these 
mice [129;130].  
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Aim of the thesis 
 
 
 This thesis intended to functionally characterize mH4R. Therefore, the 
expression of this receptor was examined on different cells of the immune system 
such as DC, macrophages, T and B cells. Furthermore, it was investigated, whether 
regulatory factors influence the receptor expression in different cell states. To 
achieve this several techniques were used, including bone marrow differentiation to 
macrophages and DC, FACS analysis, RNA isolation, RT-PCR and real-time PCR.     
 The main topic of this thesis was the functional analysis of mH4R in DC and 
macrophages. Several, functional assays were established such as chemotaxis, 
phagocytosis and cytokine production in response to histamine and other stimuli. 
These functional assays were also used to compare macrophage derived from WT 
mice with those derived from H4R -/- mice, to characterize the functions are affected 
by the absence of mH4R.  
 Another aim of this thesis was the generation of specific antibodies against 
mH4R in order to analyze mH4R on the protein level to obtain further insight on its 
function.  
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 2. Materials and methods  
 
2.1. Materials 
  
2.1.1. Mice 
 Wild type mice C57BL/6 at the age of 12-16 weeks were obtained from 
Charles River breeding Laboratories and Elevage-Janvier. H4R-knockout mice were 
generated by Lexicon Genetics (Woodlands, TX, USA) and kindly provided by 
Johnson & Johnson Pharmaceutical Research and Development (San Diego, CA, 
USA). H4R -/- mice. A 9-kb mouse genomic fragment containing the mouse H4 
receptor gene was obtained from the embryonic stem cell line 2G9 and used as a 
template to prepare the knockout construct. A 0.5-kb region covering most of exon 1 
and part of intron 1 of the H4R gene was deleted from this genomic fragment and 
replaced with a neomycin-resistant gene cassette. The mice were crossed on 
C57BL/6J background for 10 generations then have been bred between 
brother/sister pairs. The founding breeding pair provided from Johnson & Johnson 
were genotyped and found to be homozygous for the knock-out. All the knock-out 
mice in the study were derived from that breeding pair.  
 Both mouse line were used for organ isolations (bone-marrow cells, lymph-
nodes, peritoneal exudates cells and splenocytes) and examine in-vivo 
Leishmaniasis model as well as generating mouse anti-mH4R. The isolated organs 
were subjected either to RNA isolation and gene expression determination, or 
cultured to generate in-vitro cells such as bone-marrow derived macrophages or DC. 
The mice breeding and raising conditions were approved by the Central Animal 
Laboratories (ZTL) department of the University of Regensburg. 
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2.1.2 Cell lines 
 The cell lines used in the experiments were RAW 264.7, J774.1 and Pu5-1.8 
(mouse macrophages cell line), WEHI 164H, L929 and X6310 (mouse fibroblast), LA-
4 (mouse lung epithelial), P815 (mouse mastocytoma cell line) and HEK 293 (human 
embryo kidney). 
 
2.1.3. Chemicals  
4-methylhistamine (4MEH) Biotrend (Tocris), Zurich 
5-nitrophenyl phosphate disodium salt hexahydrate 
20 mg substrate tablets  
Sigma-Aldrich, Taufkirchen 
Acrylamide solution Roth, Karlsruhe 
Agarose  Peqlab, Erlangen 
Bovine serum albumine (BSA) fraction V PAN Biotech, Aidenbach 
CFSE Sigma-Aldrich, Taufkirchen 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt 
DNA 100 bp ladder  New England Biolabs, Ipswich 
dNTP mix Promega, Mannheim 
Elisa tablets (AP Sustrate)  Sigma-Aldrich, Taufkirchen 
Ethanol, absolute J.T. Baker, Deventer 
Ethidium bromide 10 mg/ml Promega, Mannheim 
Famotidine Sigma-Aldrich, Taufkirchen 
Fetal calf serum (FCS) PAN Biotech, Aidenbach 
Fluoresbrite microparticles 0,75 µm (FITC-beads) 
(1.08 x 1011 beads/ml) 
Polysciences, Eppelheim 
fMLP (N-Formy-methionyl-leucyl-phenylalanine) Sigma-Aldrich, Taufkirchen 
Histamine (2-(imidazol-4-yl) ethylamine) Sigma-Aldrich, Taufkirchen 
IFN-α Abd Serotec, UK 
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IFN-γ Abd Serotec, UK 
IL-4 Immunotools, Friesoythe 
Isopropanol Merck, Darmstadt 
JNJ 7777120  
(1-(5-chloro-1H-indol-2-yl)carbonyl-4-
methylpiperazine) 
Johnson & Johnson, San 
Diego, USA 
Lipopolysaccharide (LPS) from E. coli  
(0127:38) 
Sigma-Aldrich, Taufkirchen 
Mepyramine Sigma-Aldrich, Taufkirchen 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Taufkirchen 
Naphtyl-ethylenediamine dihydrochloride (NEDD) Sigma-Aldrich, Taufkirchen 
NOWA solution A and B MoBioTec, Heidelberg 
Nuclease free water  Promega, Mannheim 
Oligo(dt) Promega, Mannheim 
Penicillin/streptomycin (10000 Units/ml and 10 
mg/ml respectively)  
PAA Laboratories, Cölbe 
Pep.89064,1 - BSA conjugate (2nd ECD of mH4R) Biogenes, Berlin 
Pep.89064,1 - KLH conjugate (2nd ECD of mH4R) Biogenes, Berlin 
Pep.89065,2 - BSA conjugate (3rd ECD of mH4R) Biogenes, Berlin 
Pep.89065,2 - KLH conjugate (3rd ECD of mH4R) Biogenes, Berlin 
Phosphoric acid, H3PO4 Sigma-Aldrich, Taufkirchen 
Precision plus protein all blue standards Bio-Rad Laboratories, 
München 
RPMI 1640 medium PAN Biotech, Aidenbach 
Sodium nitrite Sigma-Aldrich, Taufkirchen 
Sulfanilamide Sigma-Aldrich, Taufkirchen 
Sulforic acid 2N Sigma-Aldrich, Taufkirchen 
TMB substrate solution for ELISA (A and B BD Biosciences, Heidelberg 
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substrates) 
TNF Peprotech, Hamburg  
Trypan blue Sigma-Aldrich, Taufkirchen 
Türk’s solution Merck, Darmstadt 
Tween 20 Sigma-Aldrich, Taufkirchen 
β-Mercaptoethanol Sigma-Aldrich, Taufkirchen 
 
2.1.4. Enzymes 
DNase Macherey-Nagel, Düren 
goTaq green polymerase Promega, Mannheim 
iQ™ SYBR® Green Supermix Bio-Rad Laboratories, 
München 
M-MLV reverse transcriptase Promega, Mannheim 
Pronase E Sigma-Aldrich, Taufkirchen 
Proteinase K Sigma-Aldrich, Taufkirchen 
Taq polymerase  Institute of Immunology, 
Regensburg 
 
2.1.5. Kits 
Diff-Quick® staining set DAED Behring, Marburg 
IL-6 ELISA R&D Systems, Wiesbaden 
Nucleospin RNA II (RNA isolation) Macherey-Nagel, Düren 
TNF ELISA R&D Systems, Wiesbaden 
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2.1.6. Antibodies 
 antibody source clone conjugate  dilution provider 
anti-B220   Rat RA3-6B2 PE 1:400 BD 
anti-CD11b   Rat M/170 FITC 1:200 AbD Serotec 
anti-CD11c   Hamster N418 PE 1:100 AbD Serotec 
anti-CD3   Rat 17A2 APC 1:200 BD 
anti-CD4   Rat RM4-5 PE 1:400 BD 
anti-CD8   Rat 53-6.7 PE 1:400 BD 
anti-CD86   Rat GL-1 FITC 1:200 BD 
anti-F4/80 Rat BM-8 PeCy5 1:200 AbD Serotec 
anti-FcγR Rat 2.4G - 1:500 BD 
anti-MHC II   Rat M5/114.15 APC 1:150 Miltenyi 
anti-mouse H4R  Goat Polyclonal  - 1:100 Santa Cruz (sc-3397)  
anti-mouse IgG  
(whole molecule) 
Goat Polyclonal AP 1:10000 Sigma-Aldrich 
anti-mouse IgG  
(whole molecule) 
Goat Polyclonal HRP 1:10000 Sigma-Aldrich 
 
2.1.7. Oligonucleotides 
 All oligonucleotides used for PCR and RT-PCR were purchased lyophilized 
from Metabion, and stored in -20 ° C at a concentra tion of 100 µM. The primers were 
used at the concentration of 0.3 µM in the PCR.    
 
Primer Sequence 
H1R_fwd 5’ ATGGGAAAACTGCTGTGGAG 3’ 
H1R_rv 5’ TACAGCACCAGCAGGTTGAG 3’ 
H2R_fwd 5’ GCAAGCCACAACTCTCACAA 3’ 
H2R_rv 5’ GCTCAGGCTCAGGAGACAAC 3’ 
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H3R_fwd 5’ AGCTGTGGCTGGTGGTAGAC 3’ 
H3R_rv 5’ CGGACAGGTACTCCCAACTC 3’ 
H4R_fwd 5’ TTCCTCGTGGGTTTGATTTC 3’ 
H4R_rv 5’ GCCAGTGTGTTGAGCCCTAT 3’ 
β-actin_fwd 5’ TGACGGGGTCACCCACACTGT 3’ 
β-actin_rv 5’ CTAGAAGCATTTGCGGTGGAC 3’ 
18S_fwd 5’ GTAACCCGTTGAACCCCATT 3’ 
18S_rv 5’ CCATCCAATCGGTAGTAGCG 3’ 
JNJ11-31 5’ GGAAATTGCCACCACAAGTTG 3’ 
JNJ11-32 5’ GCAGACACATGATTCTTATTAC 3’ 
Neo3b 5’ TTCTATCGCCTTCTTGACGA 3’ 
 
2.1.8. Instruments  
Bioimaging system, Genius  Syngene, Darmstadt 
Biophotometer, 6131 Eppendorf, Hamburg 
Cellsafe Cells incubators Integra bioscience, Fernwald 
Centrifuge 5417R  Eppendorf, Hamburg 
Centrifuge 5810R  Eppendorf, Hamburg 
Emax Microplate Reader Molecular Devices, München 
FACSAria system BD Biosciences, Heidelberg 
Fastblot B34 Biometra, Göttingen 
Film developer Optimax Typ TR MS Labordevices, Heidelberg 
Hera safe Safety cabinet  Heraeus, Berlin 
iQ™5 Multicolor Real-Time  
PCR Detection System 
Bio-Rad Laboratories, München 
LSR II FACS system BD Biosciences, Heidelberg 
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Microscope Leitz Diaplan Ernst Leitz Wetzlar, Wetzlar 
My Cycler™ thermal cycler  Bio-Rad Laboratories, München 
Neubauer cell chamber Brand, Gießen 
pH-Meter Inolab WTW, Weilheim 
ThermoShaker TS-100 Biometra, Göttingen 
Vortex MS2 Minishaker IKA®, Staufen 
 
2.1.9. Laboratory materials 
100 mm square Petri dishes Sterilin Ltd, Stone, Staffs, UK 
96 well PCR plate  Peqlab, Erlangen 
Amersham hyperfilm ECL GE Healthcare, München 
Cell culture flasks 75 cm2 BD Biosciences, Heidelberg 
Cell culture multi-wells plates (6 and 96 well 
plates) 
Nunc, Langenselbold 
Cell scraper (rubber policeman) Sarstedt, Nümbrecht 
Cell Strainer 40 µm (Nylon) BD Falcon BD Biosciences, Heidelberg 
FACS tubes Sarstedt, Nümbrecht 
Film cassette Siemens, München 
Gel-Blotting-Paper Whatman® A. Hartenstein, Würzburg 
Immersion oil for microscopy (immersol) Zeiss, Oberkochen 
Microscope slide 76 x 26 x 1 mm Paul Marienfeld GmbH, Königshofen 
Mechanical external measuring gauge  
Measuring range 0 - 10 mm, Scale interval 
0.010 mm 
Kröplin, Schluechtern 
Multiwell chemotaxis chamber 48 well 
(AP48) with its accessories 
Neuro probes, Gaithersburg MD, USA  
Petri dishes 100 mm (Polystyrene) Greiner, Frickenhausen 
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Poly carbonate membrane 5.0 µm 
PVP surface treatment 25 x 80 mm  
stock# PRB5 
Neuro Probes, Gaithersburg MD, USA  
Poly carbonate membrane Sandard 5.0 µm 
(PVP surface treatment) 25 x 80 mm  
Cat# 10468 
Osmonics, Minnetonka MN, USA 
Serological pipepette (5, 10 and 25 ml) Sarstedt, Nümbrecht 
Sterile filter 0.2 µm  Sartorius, Göttingen 
 
2.1.10. Buffers and Reagents 
Trypanblue solution  
  Trypan-blue 0.16 % (w/v) 
  150 mM NaCl 
  pH 7.4 
 
FACS buffer  
 2 % FCS in PBS 
 
2.1.10.1. ELISA buffers 
TBS buffer (10x): 
 (1x: 150 mM NaCl, 10 mM Tris pH 8.0) 
 87.6 g NaCl 
 12.1 g Tris 
 ~ 4 ml HCl to pH  
 Add dd H2O to 1L 
 
TBS-T:  
 TBS with 0.05 % (V/V) Tween 20 
 
 
PBS buffer (pH 7.3) Ca2+ and Mg2+-free: 
137 mM NaCl 
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6.5 mM Na2HPO4 x H2O 
1.5 mM NH2PO4 
2.7 mM KCl 
 
2.1.10.2. Western-blot buffers 
RIPA buffer: 
 50 mM Tris-base 
 150 mM NaCl 
 1 mM EDTA 
 1 % Triton X-100 (V/V) 
 0.1 % SDS (W/V) 
  1 % sodium-desoxycholat (W/V) 
 
1.5 M Tris Buffer  pH 8.8: 
90.83 g Tris-base 
Add 400 ml H2O 
Adjust pH to 8.8 with HCl 
Add ddH2O to 500 ml 
 
0.5 M Tris buffer pH 6.8: 
30 g Tris-base 
Add 400 ml H2O 
Adjust pH to 6.8 with HCl 
Add ddH2O to 500 ml 
 
4x Lämmli buffer: 
3.04 g Tris-base 
40 ml H2O 
4 g SDS 
2 mg Bromphenolblue 
Adjust pH to 6.8 with HCl 
Add ddH2O to 100 ml 
Add 4 ml β-mercaptoethanol 
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5x Running buffer: 
15.1 g Tris-base 
72 g glycine 
5 g SDS 
Add ddH2O to 1 L. 
 
Transfer buffer A: 
 36.35 g Tris-base 
 800 ml ddH2O 
 100 ml methanol 
 Adjust pH to 10.4 with HCl 
 Add ddH2O to 1 L 
 
Transfer buffer B: 
 30.03 g Tris base 
 800 ml ddH2O 
 100 ml methanol 
 Adjust pH to 10.4 with HCl 
 Add ddH2O to 1 L 
 
Transfer buffer C: 
 30.03 g Tris base 
 3.25 g ε-amino capronic acid 
 800 ml ddH2O 
 100 ml methanol 
 Adjust pH to 9.4 with HCl 
 Add ddH2O to 1 L 
 
2.1.10.3. DNA electrophoresis buffers and solutions  
TAE DNA electrophoresis buffer (50x): 
 (2 M Tris 50 nM EDTA) 
 484 g Tris-base 
 114.2 ml glacial acetic acid 
 200 ml 0.5 M EDTA pH 8.0 
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 Add ddH2O to 2 L 
 
0.5 M EDTA pH 8.0: 
 148 g EDTA 
 Adjust pH by NaOH (30-40g) 
 Add ddH2O to 1 L 
 
Loading Dye 6 x  
 40 g Saccharose 
 250 mg Bromphenolblue 
 250 mg Xylencyanol 
 Add ddH2O to 1 L 
 
2.1.10.4. Griess reagent 
(1:1 mixture of the following two solution) mix directly before use: 
1) 1% sulfanilamide 5% H3PO4 (W/V) 
10 g sulfanilamide 
50 ml  H3PO4 
Add ddH2O to 1 L 
Store at 4° C 
2) 0.1% naphtyl-ethylenamine dihydrochloride (NEDD) (W/V): 
 1 g NEDD 
Add ddH2O to 1 L 
Store at 4° C for a few weeks, as long as the the c olor has not turned to pink 
 
2.1.10.5. Genomic DNA isolation solutions and buffers 
NaCl 6M: 
  351 g NaCl 
  Add ddH2O to 1 L 
 
Pronase E solution: 
 100 mg Pronase 
 10 mM Tris-HCl pH 8.0 
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 10 mM NaCl 
 Add ddH2O to 10 ml 
  Activation for 1 h at 37° C before use 
 
Proteinase K solution: 
  10 µg Proteinase K 
  10 mM Tris pH 8.0 
  10 mM NaCl 
  1% Triton X-100 (V/V) 
  10 mM EDTA  
  1% SDS (W/V) 
  in 500 µl ddH2O 
 
2.1.11. Cell culture media 
2.1.11.1. BMDM medium 
  In 500 ml RPMI 1640 medium bottle: 
  50 ml FCS 
  5 ml Penicillin and streptomycin solution (contains 10.000 Units/ml and 10 
 mg/ml respectively)    
  50 ml of L-929 cells supernatant medium (sterile filtered)  
 
2.1.11.2. BMDC medium 
  In 500 ml RPMI 1640 medium bottle: 
  50 ml FCS 
  5 ml Penicillin and streptomycin solution (contains 10000 Units/ml and 10 
 mg/ml respectively)  
  50 ml of X6310 cells supernatant medium (sterile filtered) 
2.1.11.3. General cell culture medium  
  In 500 ml RPMI 1640 medium bottle: 
  50 ml FCS 
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  5 ml Penicillin and Streptomycin solution (contains 10000 Units/ml and 10 
 mg/ml respectively)  
 
2.1.12. Synthesized peptides 
 Two peptides were synthesized representing two different epitopes of the 
mH4R sequence. The first peptide is a 19 amino acids peptide second extra-cellular 
domain (2nd-ECD), and the second peptide is 10 amino acids third extra-cellular 
domain (3rd-ECD) (Table 2.1). The peptides were coupled either to KLH to be used 
for immunizing the mice, or to BSA to screen the mice sera for antibody generation. 
All peptides were provided by (BioGenes, Berlin) at concentration of 5 mg/ml 
potassium-phosphate buffer. 
 
Peptide Sequence 
2nd-ECD 
 
3rd-ECD 
   DSWKNSTNTKDCEPGFVTE 
 
   YPRTERPKSV 
 
Table 2.1: The sequences of peptides used to immunize H4R -/- mice and generate antibodies. 
 
2.1.13. Software 
 The figures as well as the statistical analyses were performed by Microsoft 
Office 2003® and GraphPad Prism 4®. The agarose photos were taken by GeneSnap 
6® software. Analyses of the FACS data were performed by BD FACSDivaTM 5.0.3 
and FlowJo 8.7.1 softwares.  
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2.2. Methods 
 
2.2.1. Cell culture techniques 
 
2.2.1.1. Cell lines 
 
2.2.1.1.1. Macrophages like cell lines 
 RAW 264.7, J774A.1, and Pu5-1.8 were cultured in general cell culture 
medium (see 2.1.11.3.). The cells were incubated in incubators with 95% humidity 
and 5% CO2 at 37° C. The cells grow as adherent monolayer cel ls, and were split 
twice per week by mechanically scraping the cells using a rubber cell scraper before 
full confluently grow. Some morphological changes were observed after multiple 
passages for RAW 264.7 cells. These were associated with a different expression 
pattern of the histamine receptors (mainly H4R). Therefore, those cells were replaced 
every 8-10 weeks with a new aliquot from liquid nitrogen-frozen cells.  
 
2.2.1.1.2. Supernatant isolation of L-929 and X6310 cells 
 The supernatants of L-929 and X6310 were used as a source of M-CSF and 
GM-CSF, respectively. The cells grow as adherent monolayer cells with the general 
cell culture medium. The cells were split twice per week and the supernatant medium 
was collected from the 3-4 day old cultures and filtered with 0.2 µm sterile filter, and 
stored at -20° C to be used as a supplementary medi um in BMDM and BMDC 
medium.  
 
2.2.1.1.3. Other mouse cell lines 
 WEHI 164H, LA-4, and P815 were cultured with the general cell culture 
medium. The non-adherent cells P815 were split twice per week, and kept below 
1x106 cells/ml, whereas the adherent WEHI 164H and LA-4 cells were split twice per 
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week before fully confluent grow by mechanically scraping the cells using a rubber 
scraper.   
 
2.2.1.2. Mouse primary cell isolation and in-vitro generated cells 
2.2.1.2.1. BMDM differentiation 
 The protocol used to generate BMDM was obtained from several reports with 
minor modifications [131;132]. In order to isolate bone marrow cells from C57BL/6 or 
H4R -/- mice were euthanized by cervical dislocation. The tibias and femurs were 
removed, cleaned from the muscle with a napkin, and incubated in Petri dishes 
containing ice-cold PBS. The bones were then sterilized by short incubation for 15 
seconds in 70% ethanol, and then moved to sterile chilled PBS. Bone marrow cells 
were obtained by cutting the ends of the bones under sterile conditions, and flushing 
the bone marrow cells out with chilled PBS using a 27G needle, the cells were 
counted with Türk’s solution to exclude the erythrocytes, and 10x106 cells were 
seeded in 20 ml BMDM medium (see 2.1.11.1.) in 10 x 10 cm Sterilin square dishes, 
and incubated in humid incubator at 37° C with 5% C O2 for 7 days. On day 5, the 
non-adherent cells were discarded with the old medium and replaced by fresh 20 ml 
BMDM medium. BMDM cells were also generated in 6-well plates similar to the 
previous protocol, but bone marrow cells were seeded at 1x106 cells in 4 ml BMDM 
medium. Macrophage markers were analyzed on day 7 by FACS to ensure the 
successful differentiation (see 2.2.3.1.).    
 
2.2.1.2.2. Isolation of mouse peritoneal macrophages 
 In order to enhance yield of peritoneal exudates cells (PEC) and macrophages 
harvested from the peritoneal cavity, sub-inflammation induction prior to the harvest 
is essential. Such inflammatory induction was generated by injecting 1 ml sterile PBS 
with a 25 G needle in the peritoneal cavity; 14 hours later the mouse was euthanized 
by decapitation. After sterilizing the abdomen with 70% ethanol, 10 ml of chilled PBS 
containing 10% FCS were used for peritoneal lavage, the procedure was to use 20 
ml syringe attached to 19 G needle, and inject the medium in the intact peritoneal 
cavity, with the beveled end of needle facing up without hitting the intestine. After 
gently removing it, the same needle was reinserted in the upper part of the 
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peritoneum, with the beveled end of needle facing down, and the peritoneal fluid was 
withdrawn slowly. The peritoneal exudates cells were amounted to be around 2x106 
cells per mouse, and were seeded at 1x106 in 60 mm cell culture dishes for 2 hours 
to ensure macrophages adherence. Non-adherent cells were discarded, and only 
adherent cells were used for RNA isolation or phagocytosis assays. The samples 
with PEC above 2x106 were discarded because this might indicate a bacterial 
infection in the peritoneal cavity.    
 
2.2.1.2.3. BMDC differentiation 
 Bone marrow cells were obtained as mentioned before (see BMDM 
differentiation). 2x106 cells were seeded in 10 ml BMDC medium (see 2.1.11.2.) in 10 
cm Petri dishes, or 2x105 cells in 1 ml BMDC medium in 24 well plate. On day three 
the cells were supplied with additional (10 or 1) ml fresh medium, respectively. On 
day six 10 or 1 ml respectively from the supernatant were centrifuged and the pellet 
was resuspended in a fresh (10 or 1) ml medium and added to the original dish. On 
day eight, the same step as in day six was repeated. The cells on day 8 were 
considered as immature DC which express CD11c, the specific mouse DC marker. 
The cells could be incubated for longer time up to day 10 when new medium is 
frequently supplied. BMDC were detached from the dishes by vigorously aspiring the 
medium with the pipette [133]. 
 
2.2.1.2.4. Spleen and lymph-nodes cells 
 C57BL/6 mice were euthanized by cervical dislocation. Spleen, axillary and 
brachial lymph-nodes were immediately isolated and incubated on chilled PBS. 
Organs homogenization was performed by pressing them through a cellular strainer 
(40 µm) with a syringe plunger. The cells and the strainer were washed with 10 ml of 
chilled PBS and resuspended to ensure the cell separation and formation of single 
cell suspension. Afterwards, spleen and lymph node cells were used for RNA 
isolation, or stained by specific antibodies for FACS experiments (spleen only). 
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2.2.1.2.5. Spleen macrophage preparation 
 
 In order to study the macrophages residing in spleen, the spleen single cell 
suspension was prepared and the cells were left for 2 hours in 10 cm Petri dishes to 
adhere. After that, the non-adherent cells were washed away, and the adherent cells 
were washed by PBS and gently scraped by rubber scraper and analyzed by FACS, 
after staining the cellular markers with labeled-antibodies (see 2.2.3.1.).  
 
2.2.1.3. Cell stimulation, maturation and activation  
2.2.1.3.1. Classical and alternative activation of BMDM 
 In order to generate M1 macrophages by classical activation, LPS (E. coli) was 
used at a concentration of 100 ng/ml for 24 h, or IFN-γ at a concentration of 50 IU/ml 
for 24 h. The activation was performed with BMDM generated in 6 wells plates. 
BMDM alternative activation to generate M2 macrophages was performed by 
incubating BMDM with IL-4 for 24 h at a concentration of 50 ng/ml. M1 and M2 
macrophages were later subjected to RNA isolation and real-time PCR experiments 
to quantify the mH4R expression.  
 
2.2.1.3.2. RAW 264.7 cells stimulation 
 RAW 264.7 cells were seeded in 6 well plates for 24 hours at a concentration 
of 2 x 105 in 3 ml medium. Later, medium was substituted with medium alone or 
medium containing IFN-α (120 IU/ml), IFN-γ (50 IU/ml), and TNF (50 ng/ml) 
separately for 3, 6 and 24 hours. At each time point, the stimulated and non-
stimulated cells were harvested to isolate RNA for real-time PCR. 
 
2.2.1.3.3. BMDC maturation 
 BMDC were incubated on day 8 with 100 ng/ml LPS for 24 hours in order to 
induce the maturation. The maturation was examined by FACS to inspect the 
expression of CD86 and MHC II (mature DC markers) among the CD11c positive 
population. 
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2.2.1.3.4. BMDC maturation with histamine and 4MEH in the presence or 
absence of LPS 
 BMDC generated in 24 well plates were incubated on day 8 with 10 µM 
histamine or 10 µM 4MEH. As positive control, cells were incubated with 10 ng/ml, or 
50 ng/ml LPS alone or with histamine and 4MEH separately (10 µM). As negative 
control, cells were incubated with 10 µl/well sterile H2O. The experiment was 
performed in duplicate for each incubation condition, and the cells were analyzed by 
FACS on the next day for maturation markers (CD86 and MHC class II). 
 
2.2.2. Molecular biology techniques  
2.2.2.1. RNA isolation and quantification 
 Nucleospin RNA II kit from Macherey-Nagel was used to isolate total RNA 
from different cells according to the supplier’s instructions. The principle of the 
method is to lyse the cells using the provided lysis buffer plus β-mercaptoethanol, 
and then RNA and genomic DNA were precipitated with 70% (V/V) ethanol which 
adsorb on the provided silica column. Contaminating genomic DNA was digested 
with DNase, followed by several washing steps to remove salts and protein lysate, 
and finally the total RNA was eluted with RNase and DNase free water. 
The RNA was quantified by measuring the absorbance of diluted solutions (1:25) with 
spectrophotometer at 260 nm, and the purity was determined by absorbance ratio at 
260/280 to be 1.6 - 2.0. 
 
2.2.2.2. cDNA synthesis 
 1 µg total RNA was later subjected to synthesize cDNA (Promega two-step 
RT- PCR) with 0.5 µg Oligo(dt), 10 mM dNTP mix, and 100 unit M-MLV RT using the 
supplied reaction buffer. The mixture was incubated at 48° C for 50 min for the first 
strand cDNA synthesis, then the reaction was inactivated by incubation at 70° C for 
15 min. 
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2.2.2.3. Polymerase chain reaction (PCR) using cDNA 
 The expression of histamine receptors H1, H2, H3, H4, and β-actin (positive 
control) were determined by PCR technology using specific primers (see 2.1.7). The 
amplification was performed with 160 ng cDNA, 0.5 µM of each primer (forward and 
reverse) and GoTaq polimerse (Promega). The following PCR program was used:  
   
  (First step 1 cycle)  94° C   3 min 
  (Second step 35 cycle) 94° C  30 sec 
      57° C  30 sec 
      72° C  1 min 
  (Third step 1 cycle)  72° C  5 min 
  (Forth step 1 cycle)  16° C  ∞ 
   
2.2.2.4. Genomic DNA isolation 
 Genomic DNA was isolated from all H4R -/- mice tails to perform genotyping. 
Mouse tail (0.6 cm ) was incubated overnight with 500 µl lysis buffer (QIAGEN), 10 µl 
Proteinase K and 25 µl activated Pronase E (pre-incubation for 1 hour at 37° C). The 
proteins was precipitated with 6M NaCl by shacking it for 10 min at room 
temperature. The undesired protein and unlysed debris were centrifuged and the 
supernatant was collected in a new cup. The DNA content was precipitated with 
isopropanol, and the pellet was washed with ethanol 70% (V/V) and left to dry out in 
room temperature for at least 15 min. The pellet was dissolved in 75 µl RNase and 
DNase free water, and stored at -20° C. 
 
2.2.2.5. DNA quantification  
 The DNA was quantified by measuring the absorbance of diluted solutions 
(1:25) with spectrophotometer at 260 nm, and the purity was measured by 
absorbance ratio at 260/280. The purity of all samples was between 1.6 - 2.0. 
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2.2.2.6. Agarose gel electrophoresis  
 PCR products were separated in 1% (W/V) agarose gel in TAE buffer with 0.4 
µg/ml ethidium bromide. PCR samples were mixed with 6x loading dye (see 
2.1.10.3.), and 20 µl were applied per well with the appropriate DNA ladder. 
Electrophoresis was performed at 90 volts for 50 min. The gel was visualized by UV 
light and photographed.    
 
2.2.2.7. H4R -/- mice genotyping 
 The mice were genotyped was performed by PCR according to the 
instructions fro Johnson & Johnson with two sets of primers (Fig. 2.1). Primers 
(JNJ11-31 forward primer located 166 bp upstream of exon 1, and JNJ11-32 reverse 
primer located 314 bp downstream to exon 1) should give a PCR product of 722 bp 
band only with WT genomic DNA. The other primer set is Neo3b (forward primer 
located at the 3' of the selection Neomycin cassette) and JNJ11-32. These primers 
should give a PCR product of 410 bp only with H4R -/- genomic DNA. Therefore, all 
genomic DNA from H4R -/- mice were tested with both primer pairs. 
 
 
 
Exon 1
ATG
JNJ11-31 JNJ11-32
ATG
IRES-LacZ/MC1-neo
JNJ11-31 JNJ11-32
Neo3b
WT
H4R -/-
 
 
Fig. 2.1: the localization of primers in the gene map of WT and H4R -/- mice.   
 
Genotyping PCR was performed as follow: 
 200 ng    genomic DNA 
 1 µl     dNTP mix  
 5 µl (of 10 mM solution) forward primer 
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 5 µl (of 10 mM solution) reverse primer 
 5 µl     5x Taq polymerase buffer  
 1 µl     Taq polymerase  
 H2O to 50 µl. 
The PCR cycle details is:  
 (First step 1 cycle)  94° C   3 min 
 (Second step 35 cycle) 94° C  30 sec 
     57° C  30 sec 
     72° C  1 min 
 (Third step 1 cycle)  72° C  5 min 
     16° C   ∞ 
 
2.2.2.8. Real-time PCR 
 The real-time PCR was performed in IQ5 real-time PCR detection system 
(Biorad) with 0.25 µM of each primers, 50 ng of cDNA per well, and Sybergreen (iQ 
SYBR-Green supermix) as fluophore. The detailed reagents and volumes were: 
     12.5 µl iQ SYBR-Green supermix 
     1 µl   5` primer (5 µM)  
     1 µl   3` primer (5 µM)  
     5.5 µl   Nuclease free H2O  
     5 µl  cDNA 
18S RNA was used as an endogenous house keeper to assess relative changes in 
mRNA amounts between samples. In the experiment setup, the target gene (mH4R) 
and the house keeper were done in duplicate for each cDNA sample. The PCR 
protocol program was: 
 (First step 1 cycle)  95° C   3 min 
 (Second step 50 cycles) 94° C  10 sec 
     57° C  30 sec 
     60° C  30 sec 
 Melting curve step:  95° C  1 min 
     57° C   10min 
     57° C  30 sec (77x) 
     16° C   ∞ 
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Sybergreen binds to the double-stranded DNA. This binding is detected by 
fluorescence of 521 nm emission wavelength after excitation at 494 nm. Real-time 
assay determine the time during cycles when amplification of PCR product is first 
detected, that cycle is referred as threshold cycle (Ct). Therefore, the higher starting 
copy number of the gene the faster the PCR product appears which mean lower Ct 
value. ∆Ct is calculated as follow: 
  ∆Ct = average Ct (18s) - average Ct (mH4R) 
 
This value was used to calculate (2-∆Ct) or the comparative quantification, this 
calculation is important in order to normalize differences in the mRNA extractions and 
efficiency of the reverse transcription. The relative mRNA expression or -fold 
changes of H4R gene in each sample was compared to the control sample which was 
referred as a value of one [134;135].  
 
2.2.3. Fluorescence activated cell sorter (FACS) technique 
2.2.3.1. Examine the cellular markers of macrophages  
 BMDM on day 7 were gently scraped with rubber scraper and counted with 
trypan blue to visualize the dead cells. Around 5x105 living cells were and 
resuspended in 100 µl FACS buffer and blocked with anti-FCγR (1:500) antibodies 
for 20 min on ice to avoid the unspecific binding of the labeled-antibodies on FcγR. 
FITC-labeled anti-CD11b antibodies and PeCy5-labeled anti-F4/80 antibodies were 
added to the cells and incubated for 20 min on ice in the dark. The cells were washed 
twice with FACS buffer, resuspended in 500 µl FACS buffer and analyzed in BD LSR 
II FACS® system according to the manufacturer’s instructions. One tube containing 
unlabeled cells was used to set the auto-fluorescence value of the cells, in order to 
define the positive cells. Macrophage population was characterized as CD11b and 
F4/80 double positive cells. Bone marrow cells were analyzed in a similar procedure 
to determine the percentage of macrophages in bone marrow cells before 
differentiation to BMDM. 
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2.2.3.2. Examination of the cellular markers of BMDC 
 BMDC on day 8 were collected by vigorously aspiring the medium. The cell 
count, blocking, as well as washing steps were performed similar to BMDM. The cells 
were later stained with PE-labeled anti-CD11c antibodies as a specific marker of 
mouse DC, FITC-labeled anti-CD86 and APC-labeled anti-MHC II antibodies as 
markers of the DC maturation. Cells stained with each antibody separately were used 
to set the compensation of FACS system, this step is necessary to avoid the overlap 
between the fluorophore emission wavelength. Unstained cells were used to set the 
auto-fluorescence range.  
 
2.2.3.3. Sorting mature and immature BMDC with cell sorter 
 BMDC stimulated with LPS for 24 h were subjected to staining with PE-labeled 
anti-CD11c antibodies, FITC-labeled anti-CD86 antibodies and APC-labeled anti-
MHC II antibodies. After blocking with anti-FcγR, single staining with each of the 
previous antibody was performed to adjust the compensation of cell sorter. After a 
washing step, the cells were analyzed by BD FACS Aria cell sorter, and separated 
into two populations: (CD11c+, CD8-, and MHC II-) and (CD11c+, CD8-, and MHC II-). 
Sorting was performed by first gating the CD11c positive cells, and among this cell 
population sort the cells to immature BMDC (CD86-/MHC II-) and mature BMDC 
(CD86+/MHC II+). The sorted cells were collected in FACS tubes containing 1 ml 
FCS; the cells were kept on ice and proceeded to RNA isolation.   
 
2.2.3.4. Sorting CD4+ T cells, CD8+ T cells and B cells from mouse spleen 
 Splenocytes from 13 week-old female C57BL/6 mouse (see 3.1.2.4.) were 
divided into three parts and stained with labeled-antibodies as follow: APC-labeled 
anti-CD3 antibodies and PE-labeled anti-CD4 antibodies to stain CD4+ T cells, or with 
APC-labeled anti-CD3 antibodies and PE-labeled anti-CD8 antibodies to stain CD8+ 
T cells, or with PE-labeled anti-B220 to stain B cells. After washing with FACS buffer, 
CD4+ T cells (CD3+ and CD4+), CD8+ T cells (CD3+ and CD8+) and B cells (B220+) 
cells were collected in FACS tubes containing 1 ml FCS; the cells were kept on ice 
and proceeded to RNA isolation. 
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2.2.4. Cellular functional assays  
2.2.4.1. BMDM chemotaxis assay 
 Chemotaxis assay was performed in a Neuro Probe 48-Well Micro Chemotaxis 
Chamber ® according to the provider instructions, the protocol was reported by Falk 
et al. in 1981 with minor modifications [136]. Chemotaxis medium used in the assay 
was RPMI containing 1% BSA (W/V). Six bottom wells for each concentration were 
filled either with 27 µl (has to form a slight meniscus to prevent air bubbles when the 
filter is applied) of pre-warmed medium alone as negative control, or with 
chemoattractant (4MEH or fMLP as a positive control) diluted with the previous 
medium. fMLP was used as positive control at concentration of 10 nM. Poycarbonate 
PVP-coated filter with 5 µm pore size was used to separate the bottom wells from the 
upper wells. The chamber was incubated at 37° C wit h 5% CO2 for 25 min to ensure 
the gas equilibration before filling the upper chamber with cells. BMDM cells were 
gently scraped and resuspended in medium. Fifty µl medium containing 2 x 104 cells 
were added into the upper wells; the chamber were incubated for 1.45 h. Thereafter, 
the chamber was disassembled, and the upper side of the filter was carefully wiped 
to remove all remaining non-migrated cells. Cells adherent to the other side of the 
filter were stained with Diff-Quick staining kit and were counted on the microscopy. 
The counting procedure was to count the cells in 4 vertical frames which form the 
middle line of the each well. The obtained number was considered the number of 
migrated cells in the well. To test the chemotaxis activity of H4R, 4MEH was used as 
a selective agonist of H4R. To test the role of other histamine receptors in the 
chemotaxis activity, BMDM were incubated with 1 µM of each one of the antagonists 
(mepyramine as H1R antagonist, famotidine as H2R antagonist and JNJ 7777120 the 
selective H4R antagonist) for 10 min at 37° C before starting t he assay. All three 
antagonists were dissolved in DMSO at a concentration of 10 mM and diluted in 
medium to a final concentration of 1 µM. In order to exclude the solvent effect, cells 
incubated with 0.01% (V/V) DMSO were used as a control.  
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2.2.4.2. Phagocytosis 
2.2.4.2.1. BMDM phagocytosis of FITC-micro beads 
 Phagocytosis assay was performed with BMDM on day 7 generated in 6 well 
plates. The cells were incubated with 0.75 µm FITC-labeled polystyrene-based 
spheres (Fluoresbrite microbeads) at concentration of 5 x 107 /ml from which 0.5 
µl/ml were taken. The cells were later incubated in a humid incubator at 37° C with 
5% CO2 for 2 hours. Thereafter, the cells were washed twice with 4 ml chilled FACS 
buffer to remove free beads, before gently scraping the cells and washing them twice 
with 5 ml chilled FACS buffer. Thereafter, the cells were resuspended in 1% (W/V) 
trypan blue to quench the extracellular FITC-beads. This step is essential in order to 
distinguish between the ingested beads and the beads attached to the external 
cellular compartments [137]. Cells were later analyzed in BD LSR II FACS system to 
determine the percentage of FITC-positive cells, the cells were considered positive 
with at least one ingested bead. From the FITC-positive population the mean 
fluorescent intensity (MFI) was inspected from 3x105 cells per each sample.  
 
2.2.4.2.2. Peritoneal macrophage phagocytosis of FITC-micro beads  
 After isolating the peritoneal macrophages, the cells were incubated similar to 
the BMDM phagocytosis protocol . After 2 h, similar washing step was performed and 
5x105 cells were collected and blocked with anti-FcγR for 15 min and then stained 
with anti-F4/80 (PeCy5 labeled) for 15 min. After washing step, the cells were re-
suspended in 1 % (W/V) trypan blue and proceeded to FACS analysis. The cells 
were gated for F4/80 +/- cell populations, among the F4/80-positive cells the FITC 
signal was investigated, MFI values were measured from 3x105 cells per each 
sample. 
 
2.2.4.2.3. BMDM phagocytosis of CFSE-labeled L. major 
 L. major promastigotes were cultured on blood-agar medium in 96 well plate, 
and were split once per week. To recover the virulence activity, parasites were 
injected in the footpad of BALB/c mouse after 11 passages, and isolated and cultured 
again on blood-agar medium. Promastigotes after passage 2 were isolated from the 
culture plate and washed twice with PBS. The promastigotes pellet was incubated 
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with 1 µM of carboxyfluorescein succinimidyl ester (CFSE) (1 ml for 107 
promastigotes) in the incubator at 37° C for 10 min . Thereafter, the cells were 
washed twice with PBS 5% FCS. 
  From the CFSE-labeled promastigotes ~ 6 promastigotes / macrophage (5-
10) were added to BMDM on day 7 generated in 6 well plates. After 6h, the 
supernatant medium was discarded and the cells were washed twice on the plate, 
and then gently scraped with rubber cell scraper and washed twice on the tube with 
PBS 5% FCS. Finally the cells were fixed with PBS containing 2% (V/V) FCS and 2 
% para-formaldehyde for 15 min. The cells were later used in FACS system to 
investigate the percentage of CFSE positive cells. To setup the auto-fluorescence 
value, macrophages without CFSE-labeled promastigotes were used. 
 
2.2.4.3. Nitric oxide production 
 The nitric oxide (NO) production was determined using Griess reagent (see 
2.1.9.4.) the reagent was prepared directly before performing the assay. NO 
production was determined in the supernatant of LPS and IFN-γ activated BMDM for 
at least 48 hours (NO accumulation). In 96 well plate, 100 µM sodium nitrite was 
used to prepare six points standard curve, by serial diluting till 3.125 µM with normal 
cells medium as an assay diluent. Final volume was 100 µl per well in duplicates. 
Another 100 µl of Griess reagent were added to the wells, and then optical density 
was determined using a microplate ELISA reader set to 550 nm, after using the 
assay diluent as a blank.  
 
2.2.4.4. IL-6 and TNF ELISA 
 IL-6 and TNF were measured using commercially available kits (R&D 
Systems). The principle is to coat 96 well plate with the specific capture antibody in 
PBS overnight at 4° C. The wells were later blocked  with 1% BSA (W/V) in PBS 
(reagent diluent) for 2 hours to inhibit the unspecific binding. In the next step, 100 µl 
of samples were added, and the standard was prepared by 1:1 serial dilution of the 
standard stock solution (1000 and 2000 pg/ml for IL-6 and TNF respectively). After 2 
hours at RT the biotinylated-detection-antibodies were added for 2 hours at RT, then 
1:200 diluted streptavidin-HRP were added for 20 min. A washing step was 
performed after each step previously mentioned by aspirate the wells with 200 µl of 
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0.05% (V/V) tween 20 in PBS for 3 times. After that 100 µl of HRP-substrate (TMB 
substrate solution for ELISA, 1:1 mixture of solution A and B) were added for 20 min 
and then the reaction was stopped with 50 µl of 2N H2SO4, the optical density was 
determined using a microplate ELISA reader set to 450 nm, after using the assay 
diluent as a blank. 
 
2.2.5. Antibody generation technique 
2.2.5.1. Mouse immunization   
 Two synthesized peptides (2.1.12) were used to immunize two female mH4R-/- 
mice (9 weeks old) separately. The immunization plan is shown in (Fig 2.2.2.), which 
aims to increase the antibody production against the target peptide. Two days before 
the immunization, pre-serum was collected from both mice, in order to be used as 
negative control for the screening. The mice were immunized as follow: 
• On day 1: 100 µg peptide diluted with PBS were mixed with complete Freund’s 
adjuvant (1:1) to form emulsion using 2 syringes connected to each other via a 
metal connector. The mixture was pressed in between the two syringes 10 
time every 10 min and kept on ice for 30 min. Thereafter, 300 µl of the 
previous mixture containing 100 µg were injected in each mouse intra-
peritonealy.  
• On day 21: the same previous procedure was performed but with incomplete 
Freund adjuvant.  
• On day 25: Serum was collected from both mice in order to inspect the 
antibody production in serum. 
• On day 42: another immunization step was performed with 100 µg peptide 
without any adjuvant as a boost. 
• On day 45: serum was collected from both mice, and their splenocytes were 
isolated and frozen in liquid nitrogen.    
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Fig. 2.2.: Immunization plan to generate mouse anti-mH4R antibodies in mH4R -/- mice.  
 
2.2.5.2. Serum isolation from mouse blood  
 Mouse blood was incubated at RT for 1h and then at 4° C overnight. The next 
day, the blood was centrifuged at 1400 g for 7 min to separate the serum, sera was 
stored at -20 ° C  
 
2.2.5.3. ELISA test to determine the antibodies titer in mouse serum after 
immunization 
 ELISA test was used to screen antibody production in the immunized mice. In 
order to avoid the unspecific antibodies against KLH, the two peptides coupled to 
BSA were used in the ELISA screening test. A 96 well plate was coated with 100 µl 
containing 200 ng peptide and incubated overnight at 4° C. Washing step was 
performed three times by rinsing with TBS-T, and then the plate was blocked with 1% 
BSA (W/V) in TBS for 2 hours. From the mice serum 1:100 serum dilutions (triplicate) 
was used in 1:1 serial dilution to 1:25600, the plate was incubated at room 
temperature for 2 hours. Serum from the same mouse before immunization was used 
as negative control at the dilution 1:100. Washing step was performed as before to 
remove the unspecific binding, and then 1:10.000 detection antibody (goat anti-
mouse IgG (whole molecule) AP conjugated) were incubated for 2 hours at room 
temperature. Thereafter, washing step as before was performed and 100 µl of the AP 
substrate were added (20 mg of 4-nitrophenyl phosphate disodium salt hexahydrate 
as tablet) dissolved in 10 ml AP buffer (diethanolamine buffer). To stop the reaction 
50 µl of H2SO4 were added and the yellow color density was determined at 405 nm in 
ELISA plate reader. Optical density (OD) values were used to determine the serum 
titer, which was the dilution with double OD value of the negative control.  
 
2. Materials and methods 
 
47 
2.2.5.4. Freezing mouse spleen cells in liqud nitrogen 
 Both spleens were isolated and homogenized to prepare a single cell 
suspension. Each spleen was split in three parts and mixed (1:1) with freezing 
medium (80% FCS and 20% DMSO) at a density of 3x107 cell per tube. The cells 
were frozen at -80 ° C and then transferred in the liquid nitrogen tank.  
 
2.2.6. Protein techniques 
2.2.6.1. Cell protein lysate preparation  
 To prepare the protein lysate from the cells, 1 ml RIPA buffer per 107 cells was 
used. After mixing, the cells were centrifuged at 13000 g for 10 min at 4° C, and the 
supernatant was collected and stored in -80° C for further experiments. 
 
2.2.6.2. SDS-PAGE 
 The gel was prepared with Mini-PROTEAN 3 system from Biorad. To form the 
separation gel, a 12 % (W/V) polyacrylamide gel was prepared and left to polymerize 
at RT in the system. Thereafter, the collection gel (4% (W/V) polyacrylamide) was 
poured on the top of the separation gel and left to polymerize at RT. Sixteen µl 
containing 20 µg protein lysate + 4 µl H2O and 4 µl 4x Lämmli buffer were incubated 
for 5 min at 95° C, and then loaded in the well. A protein standard (Biorad) was used 
as molecular weight marker. The gel running step was performed with 60 mA for 45 
min.  
 
2.2.6.3. Western Blot 
 The previously separated protein lysates were blotted on PVDF membrane. 
The blotting was performed in three-buffer semi-dry blotting system. First the 
membrane was rehydrated in methanol for 1 min before soaking it in transfer buffer 
B. Whatman papers soaked with transfer buffers A, B and C were used to form the 
layers as follow (from cathode to anode):  
 3 layers Whatman paper (transfer buffer A)   
 3 layers Whatman paper (transfer buffer B)  
 Membrane (transfer buffer B) 
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 Separating gel (transfer buffer C) 
 3 layers Whatman paper (transfer buffer C) 
The layers were formed without air bubbles and bloting was preformed at 1 mA/cm2 
for 1 h. The membrane was blocked after that with 2% low-fat milk powder solution in 
TBS for 2 h, and then incubated with the primary antibodies solution (1:100 in the 
same blocking solution) over night at 4° C with sha king. The membrane was washed 
with TBS-T three times (5 min each) and then incubated with HRP-labeled secondary 
antibodies depending on the isotype of the first antibody for 1 h at RT. After washing 
(3 times 5 min each), the HRP substrate (Nowa A and B solutions) was added 
directly on the membrane in the dark before incubating the membrane with 
Amersham hyperfilm ECL in the film cassette. The film was developed in the film 
developer system. 
  
2.2.7. High-dose infection model of L. major in C57BL/6 WT and  
H4R -/- mice 
  L. major promastigotes were cultured on blood agar medium and 
isolated after three passage and washed twice with PBS. Thirty µl containing 3x106 
promastigotes were injected subcutaneously in the right footpad to generate the high-
dose infection in the mice paws. The infected and non-infected footpad thicknesses 
were weekly measured after infection by mechanical external measuring gauge, and 
the percentage of footpad swelling was calculated as the difference of feet thickness 
between the infected and non-infected paws as follow:  
 (infected foot [mm] – non-infected [mm] / non-infected [mm]) x 100. 
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3. Results 
 
3.1. The role of mH4R in DC 
 
3.1.1. BMDC expression of mH4R 
 In the aim of establishing a cellular model to study the role of mH4R in the 
immune system, the expression of mH4R in DC was investigated. In mouse model, 
DC and their subtypes exists in almost all tissues. In order to isolate a sufficient 
number, DC can be isolated from the spleen (lymphoid-tissues-resident DC) as well 
as from other tissues, or generated from bone marrow cells. BMDC were considered 
as a conventional DC generated in vitro. 
 Bone marrow cells from female C57BL/6 mice (10 weeks of age) were cultured 
in medium containing GM-CSF (see 3.1.2.3.) to be differentiated to DC as mentioned 
in Material and Methods. mRNA was isolated from bone marrow cells to inspect the 
expression of mH4R by RT-PCR. On day 8 of culture, the cells were stained with PE-
labeled anti-CD11c antibody and subjected to FACS assay to analyze the expression 
of CD11c, as a specific marker of mouse DC. The results show that 77.1% of the 
viable cells population were CD11c-positive DC (Fig. 3.1), indicating the successful 
differentiation. mRNA probe was also isolated to inspect the expression of mH4R by 
RT-PCR. 
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77.1% ± 4.2
 
 
Fig. 3.1: The expression of CD11c on BMDC cells. BMDC express CD11c, the specific marker for 
mouse DC. FACS data show that 77.1 % of the living cells on day 8 were CD11c positive (gray) 
compared to the isotype staining (white). The experiment was performed in duplicate, the percentage 
represents mean of the values and SD. 
 
 BMDC generated during 8 days in the presence of GM-CSF are immature DC. 
The cells have not encountered any antigen to be processed and presented to T 
cells, which convert the immature DC to the mature status. Mature DC are 
characterized by co-expression of CD80, CD86 and MHC II in addition to CD11c.  
In order to test for the expression of mH4R mRNA in mature BMDC, immature BMDC 
were stimulated for 24 hours with 10 ng/ml of LPS. Thereafter, mRNA was isolated. 
The expression of mH4R was analyzed by RT-PCR using cDNA from bone marrow, 
immature BMDC from day 8, and mature BMDC day 9 as templates, with the specific 
mH4R primers and GAPDH as a positive control. RT-PCR results show a specific 
band with the mH4R primers indicating the expression of mH4R on the mRNA level in 
all these cell preparations (Fig. 3.2). 
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Fig. 3.2: the expression of mH4R in immature and mature BMDC on the mRNA level. cDNA from 
bone marrow cells, immature and mature BMDC were analyzed by RT-PCR. The expected PCR 
product with the mH4R primers indicated the expression of mH4R in these cells. 
 
3.1.2. Expression of known histamine receptors in immature BMDC 
 With the aim of characterizing the expression profile of other histamine 
receptors in BMDC, RT-PCR was performed with cDNA from immature BMDC and 
mH1R, mH2R, m H3R, and mH4R-specific primers and β-actin as a positive control. 
Fig 3.3 shows H1R- H2R- and H4R-specific bands. However, no band was obtained 
with H3R specific primers (Fig. 3.3). 
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Fig. 3.3: Histamine receptor expression in immature BMDC. RT-PCR shows H1, H2 and H4 
receptors expression on the mRNA level in immature BMDC.  
 
3.1.3. Regulation of mH4R expression during bone marrow 
differentiation and maturation of BMDC 
 Since RT-PCR does not provide quantitative results, the same samples as in 
Fig. 3.2 were subjected to real-time PCR, to quantify the mRNA levels of mH4R from 
bone marrow cells, immature and mature BMDC. The expression levels were 
normalized to the ribosomal RNA 18s as a house keeper (see 3.2.8.). Real-time PCR 
results show that the differentiation of bone marrow cells to BMDC was associated 
with down-regulation of mH4R expression. The down-regulation was even stronger 
after BMDC maturation with LPS (Fig. 3.4).  
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Fig. 3.4: Expression of mH4R is down-regulated during bone marrow differentiation to BMDC 
and during BMDC maturation. Real-time PCR was performed in duplicates, and the expression of 
mH4R was calculated relative to the house keeper 18s. The expression levels are put in relation to 
mH4R expression in bone marrow cells. Data represent mean ± SD of the normalized values. 
 
 To validate the previous data with mH4R expression in mature and immature 
BMDC, WT bone marrow cells were differentiated to BMDC, and subsequently 
stimulated for 24 h with 10 ng/ml LPS. The cells were stained for CD11c, CD86 and 
MHC II with flurochrome-labeled antibodies. The labeled cells were sorted by 
FACSAria® cell sorter. The sorting procedure was first to gate for the CD11c positive 
cells, and among this cell population sort the cells into immature BMDC (CD86-/MHC 
II-) and mature BMDC (CD86+/MHC II+). mRNA was isolated from the sorted cells 
(mature and immature BMDC), and then cDNA was subjected to real-time PCR with 
specific mH4R primers and 18s as a house keeper. The data show that mature 
BMDC expressed less mRNA level of mH4R than immature BMDC (Fig. 3.5), which 
confirms the previous data of mH4R down-regulation during LPS-induced BMDC 
maturation.  
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Fig. 3.5: Mature BMDC express less mH4R mRNA than immature BMDC. Real-time PCR results of 
mH4R expression in sorted immature BMDC (CD86-/MHCII-) and mature BMDC (CD86+/MHCII+). 
Each dot represents an independent experiment, performed in duplicate, and the expression was 
normalized relative to 18s and calculated as fold of immature BMDC values. ** p < 0.005 in two-way 
ANOVA test.  
 
3.1.4. Role of histamine and 4-methylhistamine (4MEH) in the 
maturation of BMDC 
 Down-regulation of mH4R during BMDC maturation raised the question 
whether mH4R plays a role in the maturation of BMDC. In order to investigate this 
point, BMDC on day 8 were stimulated for 24 h with histamine and 4MEH in the 
presence or absence of LPS (50 ng/ml) (see 3.1.3.4.). After 24 h the cells were 
tested by FACS to determine the maturation status of BMDC population based on the 
expression of CD86 and MHC II among CD11c+ cells (Fig. 3.6.a).  
 The results show a higher percentage of mature BMDC in the cell population 
stimulated with LPS in comparison to the non-stimulated cells. No effect on 
maturation was observed by histamine or 4MEH-stimulation. Also, no synergistic 
effect was obtained by combining stimulation of LPS with histamine or 4MEH (Fig. 
3.6.b). 
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Fig. 3.6: BMDC mature and immature populations in response to LPS, histamine and 4MEH.     
A: The upper histogram shows that 83% of the cells were CD11c+ cells (DC) in the gated population. 
From this population the expression of CD86 and MHCII was inspected, this resulted in three 
populations gated in three boxes. In the gate for mature cells double positive expression of CD86 and 
MHCII is found. In the gate for immature the cells double negative expression of CD86 and MHCII is 
found, cells with low expression of CD86 and MHCII were gated in the intermediate gate. The 
experiment was performed in duplicate. B: Percentages of mature BMDC obtained from the FACS 
data. The experiment was performed in duplicate and data show mean of the values ± SD. 
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3.2. The expression of mH4R in immune organs and cells 
 
3.2.1. Spleen and lymph nodes 
 The expression of mH4R in immune organs was investigated in spleen and 
lymph nodes of female C57BL/6 mouse (10 weeks). The spleen, axillary and brachial 
lymph nodes were isolated, thereafter subjected to mRNA isolation and later to RT-
PCR. The specific PCR product size was observed with mH4R specific primers 
indicating that mH4R is expressed on the mRNA level in these organs (Fig. 3.7) 
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Fig. 3.7: The expression of mH4R on mRNA level in spleen, axillary, and brachial lymph nodes of a 10 
week old female C57BL/6 mouse. 
 
3.2.2. CD4+, CD8+ -T cells and B cells 
 In order to investigate the expression of mH4R in other immune cells, the next 
targets were CD4+ T cells (T-helper cells), CD8+ T cells (cytotoxic T cells) and B 
cells. The mouse spleen as a secondary lymphoid organ represents a suitable organ 
to isolate these lymphocytes. Therefore, the spleen from a C57BL/6 female mouse 
(11 weeks) was used to prepare a single cell suspension. Splenocytes were stained 
for CD3 and CD4, CD3 and CD8 or B220 separately with labelled-antibodies in order 
to be used in the cell sorting process. The cells were later sorted by FACS cell sorter 
which separates the cells according to their specific staining (Fig. 3.8).  
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Fig. 3.8: CD4, CD8-T cells and B cells from the spleen according to the expression of the 
specific cell markers. In the left dot-blot, CD3+ and CD4+ cells (10.5% of splenocytes) were gated 
and sorted as CD4+ T cells. In the middle dot-blot, CD3+ and CD8+ cells (6.5% of splenocytes) were 
gated and sorted as CD8+ T cells. In the right dot-blot, B220+ cells (26.5% of splenocytes) were gated 
and sorted as B-cells.  
 
 The sorted cells were subjected to RNA isolation and RT-PCR with mH4R- 
specific primers. Specific PCR products were obtained from CD4+ T cells and CD8+ T 
cells, but not from B cells, indicating that mH4R is expressed in CD4+ and CD8+ T 
cells but not in B cells on the mRNA level (Fig. 3.9) 
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Fig. 3.9: The expression of mH4R in CD4+, CD8+ T cells but not in B cells. RT-PCR was 
performed with cDNA from sorted CD4+, CD8+ T cells and B cells, β-actin was used as a positive 
control. 
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3.3. The role of mH4R in macrophages 
 
3.3.1. Screening several cell lines for the expression of mH4R 
 The initial aim of the project was to identify a cellular model to examine 
expression, regulation as well as function of mH4R. Therefore, primary and ex vivo- 
generated immune cells as well as several cell lines were screened to determine the 
expression of mH4R. Cell lines were selected from cell types or tissues where the 
positive expression was expected, such as macrophage cell lines (RAW 264.7, 
J774.1 and Pu5-1.8), mast cells (P815), fibroblasts (WEHI 164) and Lung epithelial 
cell line (LA-4). RT-PCR results (Fig. 3.35) show an expression of mH4R on the 
mRNA level.  
 
 
 
Fig. 3.10: RT-PCR shows the expression of mH4R on mRNA level in several tested cell lines. 
 
3.3.2. Isolation and characterization of macrophage populations 
3.3.2.1 Bone marrow derived macrophages (BMDM) 
 The previous results showing the expression of mH4R in macrophage cell lines 
(Fig. 3.10), in addition to the expression of human H4R on monocytes mentioned the 
literature, raised the question about possible expression of mH4R in ex vivo 
generated macrophages and primary macrophages [49]. 
 BMDM were differentiated in vitro from bone marrow cells of a 12 week old 
female C57BL/6 mouse, in medium containing M-CSF (macrophage medium) for 7 
days. FACS technique was used to monitor the macrophage population development 
during the 7 days. Macrophages were characterized as cells expressing F4/80 
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(specific macrophage marker), and CD11b (myeloid marker), the cells were analyzed 
on day 0 (bone marrow cells), day 5 and day 7. The results show a clear increase in 
the macrophage population starting from 2.9 % in bone marrow cells on day 0, to 
95.1 % on day 5, and 98.4 % on day 7 (Fig. 3.11) indicating successful 
differentiation. RNA was isolated from BMDM on day 7 to perform RT-PCR (see 
3.3.2).   
    
 
 
Fig. 3.11: Development of the macrophage population (CD11b+ and F4/80+) during bone marrow 
cells differentiation. FACS dot-plots show that bone marrow cells contained 2.9 % macrophages 
(CD11b+ and F4/80+ cells in the upper right square of the dot blot). The percentages increased to 
95.1% on day 5 and 98.4% on day 7. The experiment was performed in duplicate and the percentages 
represent the means from one of four independent experiments. 
 
3.3.2.2. Peritoneal macrophages 
 The expression of mH4R in primary mouse macrophages was analyzed in 
peritoneal macrophages. These macrophages are the largest population among the 
PEC. Two female C57BL/6 mice at the age of 12 week old were used to isolate PEC 
(see 2.2.1.2.2.). The cells were pooled from both mice and incubated to adhere for 
two hours in RPMI medium. Part of the adherent cells were subjected to RNA 
isolation (see 3.3.2), and the rest were stained with labeled antibodies for the 
expression of CD11b and F4/80 in order to determine the percentage of 
macrophages by FACS. The results revealed that 82.7 % of the whole viable cell 
population consisted of macrophages (F4/80+/CD11b+) as shown in fig. 3.12. 
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Fig. 3.12: Percentage of macrophages in PEC. Dot-plot FACS shows the macrophage population in 
the upper right square (F4/80+/CD11b+) consisting of 82.7% of the peritoneal exudate cells. The 
experiments were performed in duplicates. The figure represents one of two independent experiments. 
 
3.3.2.3 Macrophage cell lines RAW 264.7, and J774.1  
 In order to examine other types of macrophages, macrophage cell lines RAW 
264.7 and J774.1 were cultured in RPMI medium, and harvested after passage 7 for 
RAW 264.7 and passage 4 for J774.1 to isolate RNA and perform RT-PCR (see 
3.3.2).   
 
3.3.3. Expression of mH4R in mouse macrophages 
 RNA samples from BMDM, peritoneal macrophages, RAW 264.7 and J774.1 
were used in RT-PCR with specific primers for all mouse histamine receptors. 
Specific PCR-products were observed with H1R, H2R and H4R-specific primers, 
indicating that these histamine receptors were expressed on the mRNA level in all 
types of the investigated macrophages. However, no expression of H3R was 
observed in these cells (Fig. 3.13).  
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Fig. 3.13: The expression profile of histamine receptors in mouse macrophages. Several types 
of mouse macrophages were examined by RT-PCR for the histamine receptors expression. RT-PCR 
showed specific PCR products with H1, H2, H4 and β-actin specific primers H1, H2 and H4 receptors 
specific bands indicate the expression on the mRNA level, whereas H3R was not detected. 
 
3.3.4. Regulation of mH4R expression in mouse macrophages 
3.3.4.1. Regulation of mH4R expression with pro-inflammatory cytokines in 
RAW 264.7 cells  
 In order to investigate the regulation of mH4R expression in mouse 
macrophages, RAW 264.7 cells were stimulated with pro-inflammatory cytokines 
(IFN-α, IFN-γ, or TNF) for 3, 6, and 24 hours. The stimulated cells were subjected to 
RNA isolation at the indicated time points. Real-time PCR technique was used to 
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quantify the mRNA levels of mH4R in the examined samples, which demonstrated 
that the expression of mH4R is regulated in response to these stimuli in a transient 
way, while IFN-γ stimulation shows a stable up-regulation relative to the appropriate 
control (Fig. 3.14).  
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Fig. 3.14: TNF, IFN-α, and IFN-γ regulate the expression of mH4R in different kinetic patterns. 
Expression of mH4R was determined by real-time PCR after stimulating the cells with TNF, IFN-α, or 
IFN-γ for 3, 6 and 24 h. The real-time PCR experiment was performed in duplicate, and the expression 
was calculated relative to 18s. Results show the expression as fold of the value of the control cells. 
Data show the mean ± SD of the normalized values. 
 
3.3.4.2. Effect of BMDM differentiation and activation on mH4R expression 
 Based on previous data from BMDC, the question was whether the regulation 
of mH4R expression in BMDM resembles that of BMDC, since both cell types 
differentiate from bone marrow, and they share several functions in the innate 
immunity such as chemotaxis, phagocytosis and antigen presentation.  
 Bone marrow cells from female C57BL/6 mice (14 weeks) were differentiated 
to BMDM. A part of the bone marrow cells was used to isolate RNA, and the rest 
were seeded in macrophage medium. On day 7, RNA was isolated from part of the 
cells and the other cultures were activated either with IFN-γ, or with LPS for 24 h. 
After this activation time the cells were harvested to isolate RNA. Real-time PCR 
results (Fig. 3.15) clearly showed a higher expression of mH4R in bone marrow cells 
compared to BMDM. BMDM activation with IFN-γ for 24 h up-regulated the 
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expression of mH4R around 4-fold relative to control cells. Conversely, LPS-activated 
macrophages for 24 h expressed very low level of mH4R relative to the non-activated 
cells. The IL-4 activation did not show a significant effect on the mH4R expression 
level after 24 hours.  
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Fig. 3.15: Expression of mH4R is regulated during bone marrow differentiation to macrophages 
and during macrophage activation. Using real-time PCR the expression of mH4R was quantified to 
compare the expression between different cell states, A: bone marrow cells and BMDM on day 7. B: 
IFN-γ-activated BMDM for 24 h versus control cells. C: LPS-activated BMDM for 24 h versus control 
cells. D: IL-4-activated BMDM for 24 h versus control cells. Each dot represents an independent 
experiment, performed in duplicate, and expression was normalized relative to 18s and calculated as 
fold of control values. * p<0.05, ** p<0.005 in two-way ANOVA test. 
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3.3.5. Functional study of mH4R on BMDM 
3.3.5.1. Chemotaxis  
 Several publications have indicated that H4R mediates a chemotactic effect on 
several immune cells like eosinophils, DC, and human monocytes [34]. Therefore, 
chemotaxis was one of the mH4R functions investigated with mouse macrophages. In 
the assay setup, the specific H4R agonist 4MEH was used to investigate whether it 
induces any chemotactic effect in BMDM or not. 4MEH was considered as a human 
H2R agonist, but the discovery of H4R revealed that it possesses 100-fold higher 
selectivity for human H4R than human H2R. Some other data show similar results for 
the mH4R in vitro as well as in vivo [23;72].  
 
3.3.5.1.1. mH4R agonist induces chemotactic effect in BMDM 
 BMDM from day 7 culture were exposed to different concentrations of 4MEH in 
a chemotaxis chamber. After 1.45 hours, and after fixing and staining the cells on the 
filter, the migrated cells were counted under the microscope to assess cell migration 
(see 2.2.4.1.). 
 Chemotaxis assay data revealed a chemotactic effect of 4MEH on BMDM in a 
concentration dependent manner, with a peak around 100 nM of 4MEH. 
Unexpectedly, the cells showed also a significant migration in response to 100 µM of 
4MEH, which is not typical for a chemotaxis bell-shape curve (Fig. 3.16) 
[49;115;116]. 
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Fig. 3.16: 4MEH induced concentration dependent chemotaxis in BMDM. A chemotaxis assay 
was performed with BMDM day 7 in the presence of 4MEH. The cells migrated towards medium as 
negative control and towards 4MEH were counted. The experiments were performed in 6 wells for 
each concentration. Data show means ± SD, p values were calculated by two-way ANOVA test, 
representing one of at least 4 independent experiments. 
 
3.3.5.1.2. mH4R antagonist inhibited the chemotactic effect induced by 4MEH 
 
 Consequently, the next step was to answer the question whether 4MEH-
induced chemotaxis is mediated by mH4R or not. Therefore, BMDM day 7 were 
challenged with several concentrations of 4MEH in a chemotaxis assay after pre-
incubating the cells with 1 µM of JNJ 7777120 as a selective mH4R antagonist for 10 
min before starting the assay. The results show that 1 µM of JNJ 7777120 was able 
to block the cells migration up to a concentration of 1 µM of 4 MEH (Fig. 3.17). At 
higher concentrations of 4MEH the cells resumed migration.     
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Fig. 3.17: JNJ 7777120 inhibited 4MEH-induced chemotaxis in BMDM. BMDM day 7 were 
incubated with 1 µM JNJ 7777120 for 10 min before performing a chemotaxis assay towards 100 nM, 
1, 10, 100 µM of 4MEH. The experiments were performed in 6 wells for each concentration. Data 
show mean ± SD, p values were calculated by two-way ANOVA test, representing one of two 
independent experiments.   
 
3.3.5.1.3. H1 or H2 receptors do not mediate 4MEH-induced chemotaxis in 
BMDM 
 The co-expression of H1R and H2R with H4R in BMDM raised the question 
about the possible role of the other two histamine receptors in the chemotactic 
activity induced by 4MEH. Therefore, 100 nM of 4MEH was considered the suitable 
concentration to examine the chemotaxis in the presence of antagonists to H1, H2 
and H4 receptors.  
 BMDM day 7, were pre-incubated with 1 µM of mepyramine (H1R antagonist), 
famotidine (H2R antagonist), JNJ 7777120 (H4R antagonist) and 0.01% DMSO as a 
control for the famotidine and JNJ 7777120 to exclude the solvent effect, 10 nM of 
fMLP was used as a positive control. The cell count of migrated cells (Fig. 3.18) 
revealed that neither H1- or H2- receptor antagonists could inhibit the migration 
towards 100 nM 4MEH, whereas cells pre-incubated with JNJ 7777120 had a 
significant inhibitory effect on the cell migration.   
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Fig. 3.18: The role of H1, H2 and H4R antagonists in 4MEH induced chemotaxis in BMDM. BMDM 
on day 7 were pre-incubated for 10 min with 1 µM of JNJ 7777120, mepyramine and famotidine 
separately before performing chemotaxis assay towards 100 nM of 4MEH. Cells pre-incubated with 
0.01% DMSO were used in the assay as a control. The experiments were done in 6 wells for each 
concentration, data show means ± SD from one of two independent experiments, p value was 
calculated by two-way ANOVA test. 
 
3.3.6. Comparing macrophages from C57BL/6 mice to those from 
H4R -/- mice 
 H4R -/- mice were used to generate BMDM, which represent a suitable model 
to investigate the functional differences between WT and H4R -/- cells. Some of the 
main macrophage functions were used to dissect the differences between cells from 
mice these such as chemotaxis, phagocytosis, cytokine production as well as bone 
marrow differentiation to macrophages. 
 
3.3.6.1. Genotyping H4R -/- mice 
 In order to genotype the mice provided by Johnson & Johnson PCR was 
performed with genomic DNA isolated from the mice tails. The primer localisation in 
gene map of WT and mH4R -/- mice is shown in 2.2.2.7. Both primer sets (5’ JNJ11-
31 and 3’ JNJ11-32) and (5’ Neo3b and 3’ JNJ11-32) were tested with DNA from WT 
mice and H4R -/- mice. PCR results showed the expected specific band size from both 
primers with both types of DNA. In order to control the breeding process of mH4R -/- 
mice, the founding breeding pair provided from Johnson & Johnson were genotyped 
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and found to be homozygous for the knock-out. All the knock-out mice in the study 
were derived from that breeding pair (see 2.2.2.7.). 
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Fig. 3.19: Genotyping of H4R -/- mice. PCR performed with genomic DNA from a C57BL/6 mouse 
(WT) and from the breeder mouse pair provided by Johnson & Johnson (KO1, KO2). The PCR 
products were at the expected size. 
 
3.3.6.2. Chemotaxis 
 The role of 4MEH as a chemotatractant for WT-BMDM was compared to    
H4R -/- BMDM in order to further validate the previous results. Therefore, WT-BMDM 
and H4R -/- BMDM day 7 were used for chemotaxis assay in the presence of 100 nM 
and 100 µM of 4MEH.   
 Chemotaxis results revealed a significantly higher WT-BMDM migration 
towards 100 nM 4MEH compared to H4R -/- BMDM. Moreover, both types of BMDM 
migrated towards 100 µM of 4MEH (Fig. 3.20). 
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Fig. 3.20: Different chemotactic response to 4MEH between BMDM derived from WT and H4R -/- 
mice. BMDM day 7 from WT and H4R -/- were used in a chemotaxis assay with 100 nM and 100 µM of 
4MEH. The experiments were performed in 6 wells for each concentration, data show means ± SD 
from one of two independent experiments. *** p = 0.0002 calculated by two-way ANOVA test. 
 
3.3.6.3. Bone marrow differentiation to macrophages 
 In order to compare BMDM from WT and H4R -/- mice, the first step was to 
compare bone marrow cell differentiation to macrophages of both strains. For that 
purpose, the percentage of macrophages (CD11b+ and F4/80+ cells) generated from 
bone marrow cells after 7 days was considered as a marker to compare the capability 
of bone marrow cells to differentiate to macrophages. Bone marrow cells from WT 
and H4R -/- mice (similar age, sex and animal facility) were seeded in macrophage 
medium for 7 days. The number of the cells seeded per dish and the medium as well 
as the incubation conditions were strictly identical. On day 7, WT-BMDM and H4R -/- 
BMDM were analyzed by FACS to determine the percentage of macrophages 
(CD11b+ and F4/80+) generated in vitro. 
 Interestingly, the cells from H4R -/- mice contained a slightly higher number of 
macrophages in medium after 7 days than WT mice. The differences between WT 
and H4R -/- was lower when macrophage percentage was high (over 90%), whereas 
the lower macrophage percentage in culture (around 80%) showed a clearer 
difference between the two mice types (Fig. 3.21).   
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Fig. 3.21: Percentage of macrophages from H4R -/- and WT mice after 7 days differentiation. 
FACS experiments show macrophage (CD11b+ and F4/80+ cells) percentages from H4R -/- in culture 
after 7 days bone marrow differentiation to macrophages. Each dot represents an independent 
experiment (n = 11 per group), each individual experiment result was normalized to the WT values 
which were set as 100%, the age and sex were identical in each individual experiment.                     
(*** p = 0.0005, paired t-test), the data were normalized to the control values as follow: (mean H4R -/- 
/mean/mean WT) x 100. The age of the mice was between 11-16 weeks and the age and sex were 
matched in each individual experiment.  
 
3.3.6.4. Spleen macrophages 
 The previous results obtained from ex-vivo generated macrophages have 
raised the question whether H4R -/- mice have higher macrophages numbers residing 
in tissues.  
 Spleen macrophages were used to compare the actual percentage of 
macrophages existing in vivo. Therefore, the percentage of CD11b+ and F4/80+ in 
splenocytes was analyzed by FACS. The splenocytes were left to adhere to the cell 
culture Petri dishes to eliminate the non-adherent cells which are not macrophages.  
No difference was observed between the mice strains, indicating that the number of 
macrophages residing in the spleen is identical in both mouse strains (Fig. 3.22).  
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Fig. 3.22: The percentage of macrophage in adherent splenocytes of WT and H4R -/- mice. The 
percentage of macrophages isolated from spleen of 15 week old male WT and H4R -/- mice (n = 8) 
after a 2 h adherence step before analysing the cells by FACS. Data represents two independent 
experiments performed in duplicate. 
 
3.3.6.5. Phagocytosis 
3.3.6.5.1. Phagocytic activity in BMDM 
 Based on the previous results of a higher percentage of differentiated 
macrophages derived from H4R -/- mice in culture, these macrophages were tested in 
functional assays. The phagocytosis assay was used to answer the question whether 
the higher percentage of macrophages from H4R -/- mice was associated with a 
higher phagocytic activity than macrophages from WT mice. Therefore, BMDM day 7 
from the previously mentioned experiments (see 3.3.5.2.) were subjected to 
phagocytosis using FITC-labeled microbeads. FACS techniques were used to 
perform the assay (see 2.2.4.1.), and the read out was the mean fluorescence 
intensity (MFI) to assess the amount of beads ingested in the cells.  
 Despite the higher percentage of H4R -/- BMDM in culture, the WT-BMDM 
showed always significantly higher MFI values than H4R -/- BMDM. Data from six 
independent experiments showed a difference of 15 -33% between the WT and the 
H4R -/- values (Fig. 3.23), indicating that phagocytic activity in WT-BMDM is higher 
than in H4R -/- BMDM. 
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Fig. 3.23: Lower phagocytosis of BMDM from H4R -/- relative to WT mice. BMDM day 7 from WT 
and H4R -/- mice were incubated with FITC-labelled micro beads for 2 hours and then analyzed by 
FACS for the mean fluorescence intensity (MFI). Each dot represents an independent experiment (n = 
14 mice per group). Mice were 11-16 week of age and were matched in age and sex in each individual 
experiment. The data were normalized to the control MFI values as follows: MFI H4R -/- (mean) / MFI 
WT (mean) x 100. (*** p<0.0001, paired t-test). 
 
 The percentages of FITC positive cells (cells which ingested one bead at 
least) of both types did not significantly differ in both BMDM types which does not 
explain the MFI differences. Therefore, alignment of both flurescence histograms was 
performed to analyse the difference. The results showed that both types of 
macrophages can phagocyte low numbers of beads (up to three beads), but only 
WT-BMDM exhibited the capability of phagocytosing higher numbers of beads, this is 
demonstrated by a higher cell number with more than three beads ingested in 
comparison to H4R -/- BMDM (Fig. 3.24). 
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Fig. 3.24: Fewer ingested beads in H4R -/- BMDM compared to WT-BMDM. The alignment of FACS 
fluorescence histogram from WT-BMDM and H4R -/- BMDM showed the difference between both types 
according to their beads content. H4R -/- BMDM ingested fewer number of beads compared to WT 
BMDM. The data represent an example of phagocytosis histograms. 
 
3.3.6.5.2. Phagocytic activity in PEC 
 The lower phagocytic activity in H4R -/- BMDM raised the question whether 
other macrophage types have also similar phagocytic activity. To determine the 
phagocytic activity in another type of macrophages, peritoneal macrophages 
obtained from PEC were isolated and used in a phagocytosis assay. In order to focus 
on macrophage phagocytosis and exclude other cells like granulocytes in the PEC 
population which may contribute to phagocytosis, the cells were stained for F4/80 
expression after the assay. The FITC-beads fluorescence signal was determined In 
F4/80+ cells by FACS system (Fig. 3.25.A). Significant lower MFI values were 
obtained from H4R -/- compared to WT macrophages. The difference was between 
20-37% when WT values were set as 100 % activity (Fig. 3.25.B), indicating that 
peritoneal macrophages from H4R -/- show also a lower phagocytic activity than 
peritoneal macrophages from WT mice.  
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Fig. 3.25: F4/80+ cells of PEC from H4R -/- show decreased phagocytosis compared to WT mice. 
Peritoneal macrophages were isolated from WT and H4R -/- mice and incubated with FITC-micro beads 
for 2 hours, F4/80+ cells were stained before analysing the cells in FACS. (A) An example of the 
population in PEC phagocytosis. F4/80+ cells were gated and analyzed for FITC fluorescence. (B) MFI 
from WT macrophages were set as 100% activity and compared to H4R -/- macrophages. Each dot 
represents a single experiment performed in duplicate (n = 4 of 12 weeks old female mice per group). 
** p = 0.0039, two-way ANOVA test. 
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3.3.6.5.3. Phagocytosis of Leishmania major promastigotes labelled with CFSE 
 In order to validate the previous findings with another phagocytosis system 
which is closer to reality, BMDM from WT and H4R -/- were challenged with labelled-L. 
major in phagocytosis assay. As previously mentioned in the Introduction, the 
clearance of this parasite is known to be a macrophage-dependent mechanism, and 
the ingested amastigotes remain in the phagosomes before being killed by the 
macrophages [127;128].  
 Therefore, L. major promastigotes were labelled with CFSE (see 2.2.4.2.3.) 
and incubated with WT and H4R -/- BMDM day 7 for 6 hours. After washing away the 
non-phagocytosed parasites and fixing the cells, the cells were analyzed in FACS to 
determine the percentage of CFSE (FITC) positive cells. In agreement to the 
previous data, H4R -/- BMDM showed a lower percentage of CFSE-positive cells than 
WT-BMDM. The difference was between 15-26 % when WT values were set as 100 
%, indicating lower phagocytic activity (Fig. 3.26).    
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Fig. 3.26: L. major phagocytosis is impaired in H4R -/- BMDM compared to WT-BMDM. BMDM 
day 7 generated from WT and H4R -/- mice were incubated with living L. major promastigotes labelled 
with CFSE (around 6 parasites per cells). After 6 hours the percentage of CFSE-positive cells were 
determined by FACS, and calculated relative to WT values set as 100 %. Each dot represents an 
independent experiment performed in triplicate (n = 4 per group) (** p = 0.0015, two-way ANOVA test). 
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3.3.6.5.4. The role of histamine in WT-BMDM phagocytosis 
 
 The next aim was to identify the role of histamine in BMDM phagocytic activity. 
The aim was to examine whether stimulating BMDM by which histamine can 
modulate BMDM phagocytosis. Therefore, BMDM day 7 generated from two WT 
mice were used in a phagocytosis assay in the presence of serial concentrations of 
histamine. After 2 hours the cells were analyzed by FACS to determine the MFI 
levels. The results did not show any differences in the MFI levels between histamine-
stimulated and non-stimulated cells (Fig. 3.27). Similar to MFI the percentage of 
FITC-positive cells did not differ (data not shown). These findings confirmed three 
previous experiments where 1 µM of histamine did not modulate phagocytic activity 
in BMDM day 7 of wild-type mice (data not shown).  
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Fig. 3.27: Exogeneous histamine does not affect the phagocytosis of BMDM. BMDM day 7 from 
two male wild-type mice (11 weeks) were incubated with FITC-micro beads for 2 hours in the presence 
of the indicated histamine concentrations. MFI of the cells obtained by FACS showed no effect of 
histamine on phagocytosis in BMDM. The experiment was performed in duplicate, data show means ± 
SD performed in triplicate. 
 
3.3.6.5.5. The effect of JNJ 7777120 in BMDM phagocytosis 
 The previous results showed that exogenous histamine did not modulate the 
phagocytosis activity in BMDM. But the expression of HDC in macrophages raised 
the question whether BMDM produce their own histamine. This histamine could act 
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like an autocrine stimulator acting through one of the histamine receptors expressed 
on macrophages. In order to assess this hypothesis, the next step was to block H4R 
during the phagocytosis assay and examine the influence on phagocytosis. 
 BMDM day 7 generated from two WT mice were used in a phagocytosis assay 
in the presence of serial concentrations of JNJ 7777120. FACS results show that MFI 
levels did not reveal any significant effect of JNJ 7777120 in the phagocytic activity 
(Fig. 3.28). In three earlier experiments, 1 µM of JNJ 7777120 had no influence on 
phagocytosis activity (data not shown).   
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Fig. 3.28: JNJ 7777120 does not affect the phagocytosis of BMDM. BMDM day 7 from two male 
wild-type mice (12 weeks) were incubated with FITC-micro beads for 2 hours in the presence of the 
indicated JNJ 7777120 concentrations. The MFI of the cells analyzed per FACS showed no effect of 
JNJ 7777120 on phagocytosis of BMDM. The experiment was performed in duplicate, data show 
means ± SD performed in triplicate. 
 
3.3.6.5.6. BMDM generation in the presence of JNJ 7777120 
 The previous data could partially reject the hypothesis of autocrine histamine 
action. The next hypothesis was that histamine could be produced in medium during 
the 7 days cell culture, and this might lead to improved differentiation via H4R to fully 
active macrophages and less active cells when H4R is absent.     
 In order to assess this hypothesis, bone marrow cells from two wild-type mice 
were cultured either in normal BMDM medium (WT), or in the same medium with 10 
µM JNJ 7777120 (WT+JNJ). In parallel, bone marrow cells from two H4R -/- mice 
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were cultured in the same normal BMDM medium.On day 7, the cells were subjected 
to staining with anti-CD11b and anti-F4/80 in order to be analyzed by FACS. The 
number of macrophages showed that WT cells generated significantly higher 
numbers of macrophages than WT+JNJ cells, and both numbers were lower than 
macrophages from H4R -/- mice. These results showed that the presence of H4R 
antagonist did not have the same effect on macrophage differentiation than H4R-
deficiency (Fig. 3.29.A).  
 Cells were then subjected to a phagocytosis assay with FITC-microbeads. 
FACS results revealed that MFI values from BMDM of WT+JNJ and H4R -/- BMDM 
were significantly lower compared to WT BMDM. (Fig. 3.29.B). 
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Fig. 3.29: Comparing macrophages numbers and phagocytosis in cells differentiated in the 
presence of JNJ 7777120. Bone marrow cells from wild-type mice (n = 7 of 15 weeks old) were 
cultured in normal BMDM medium (WT), and in BMDM medium containing 10 µM of JNJ 7777120 
(WT+JNJ). Bone marrow cells from H4R -/- mice (n = 7 age and sex matched) were cultured in normal 
BMDM medium (H4R -/-). After 7 days, the cells were used for analyzed by FACS for CD11b and F4/80 
expression and for phagocytosis of FITC micro beads. (A) Percentage of CD11b+ and F4/80+ cells. (B) 
MFI values after phagocytosis assay normalized to WT as 100 % activity. Data represents two 
independent experiments performed in duplicate. P values were calculated by two-way ANOVA test. 
 
3.3.6.6. Production of pro-inflammatory cytokines and NO 
3.3.6.6.1. TNF and IL-6 production 
 TNF and IL-6 are pro-inflammatory cytokines produced by macrophages, and 
they are considered as markers for the classical activation of macrophages mediated 
by LPS. In order to examine the role of H4R in the production of TNF and IL-6 from 
BMDM, WT and H4R -/- BMDM day 7 generated in a 6 well plate were activated with 
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100 ng/ml of LPS for 24 hours. IL-6 and TNF concentrations were determined by 
ELISA in the supernatant.  
 After 10 hours, a clear morphological difference was observed between WT 
and H4R -/- BMDM. WT-BMDM had the distinct podosome with dendritic shape typical 
for LPS activated macrophages, unlike H4R -/- BMDM, which were more round (Fig. 
3.30). 
 
 
 
Fig. 3.30: LPS-activated BMDM from WT and H4R -/- mice. The microscopic picture shows the 
different shape between WT-BMDM and H4R -/- BMDM after activation with 100 ng/ml LPS for 10 
hours. 
 
 The morphological difference was associated with lower TNF and IL-6 
production in response to LPS. The values of TNF and IL-6 varied between different 
experiments, however the difference between BMDM from WT and H4R -/- was 
always detectable (Fig. 3.31). 
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Fig. 3.31: BMDM day 7 generated from WT and H4R -/- mice were incubated with 100 ng/ml LPS for 24 
hours. TNF (A) and IL-6 (B) concentration were determined in the supernatant by ELISA. The 
connected dots represent an independent experiment (n = 4) Determinations were performed in 
triplicates, * p < 0.05 in two-way ANOVA test.  
 
3.3.6.6.1.1. The role of histamine in TNF and IL-6 production 
 Similar to the phagocytosis aspect, the previous data raised the question 
about a possible role of histamine in TNF and IL-6 production. Therefore, BMDM day 
7 were stimulated with serial concentrations of histamine for 24 h. Thereafter, TNF 
and IL-6 concentrations were determined by ELISA. TNF and IL-6 did not show any 
response to histamine stimulation after 24 h (Fig. 3.32). Moreover, TNF and IL-6 
levels were close to the detection level of the ELISA assay, indicating that BMDM 
were not activated and the additional histamine did not change this state. In three 
other earlier experiments, BMDM day 7 cells were stimulated with 1 µM of histamine 
for 24 h. TNF and IL-6 determination did not show any effect of histamine on the 
production of the two cytokines (data not shown).  
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Fig. 3.32: No effect of exogenous histamine on TNF and IL-6 production in BMDM. BMDM on 
day 7 were incubated for 24 hours with different concentrations of histamine. The TNF and IL-6 
concentrations were determined in the supernatant by ELISA. Histamine does not change the basal 
levels of TNF and IL-6 produced by the non-stimulated cells. The experiment was performed in 
duplicate and data show means ± SD. P values were calculated by two-way ANOVA test.  
 
3.3.6.6.2. Nitric oxide (NO)  
 The impaired response to LPS observed in H4R -/- BMDM brought to the 
attention other LPS-related macrophage activities such as NO production. NO is one 
of the anti-microbial compounds secreted by macrophages and other leukocytes in 
response to several bacterial compounds such as LPS. In addition, IFN-γ secreted 
from T-cells is also essential to activate macrophages and increase the secretion of 
NO. NO levels in supernatants were determined by Griess reagent (see 2.2.4.3). In 
the experiment setup the cells were activated with LPS and IFN-γ for 48 h. The 
longer incubation time is necessary to accumulate NO in the supernatant to reach 
detectable levels in the assay. 
 In order to compare NO production between WT and H4R -/- BMDM, BMDM 
from two mice per group were generated as previously mentioned. Subsequently, on 
day 7 the cells were stimulated with IFN-γ (20 ng/ml) and 100 ng/ml LPS for 48 
hours. NO levels in the supernatant medium of WT-BMDM were clearly higher than 
H4R -/- BMDM. The NO values varied between different experiment, however the 
difference between BMDM from WT and H4R -/- was always detectable (Fig. 3.33). 
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Fig. 3.33: H4R -/- BMDM produce less NO than WT-BMDM. BMDM generated from WT and H4R -/- 
mice were incubated with LPS (100 ng/ml) and IFN-γ (20 ng/ml) for 48 hours. NO concentrations were 
determined in the supernatant. WT-BMDM showed a higher accumulative NO production than H4R -/- 
BMDM. The connected dots represents an independent experiment performed in duplicate (n = 5 per 
group). ** p<0.005 in two-way ANOVA test.  
 
3.3.6.6.2.1. The role of histamine in NO production in BMDM  
 Similar to what was observed for the cytokines production, the direct effect of 
histamine on NO production had to be investigated. In this line, BMDM generated 
from WT mice were stimulated on day 7 with 1 µM histamine, 0.1% (V/V) DMSO and 
1 µM JNJ 7777120 in the presence or without LPS 100 ng/ml for 48 h. 
 As expected, the cells without LPS did not produce NO, also not after 
histamine stimulation, whereas LPS treated cells show a clear detectable NO level. 
Histamine had a slight inhibitory effect on the NO production in LPS treated cells. 
However, this inhibition was not reversed when the cells were cultured in the 
presence of JNJ7777120 (Fig. 3.34). 
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Fig. 3.34: No effect of histamine on NO production in BMDM. BMDM day 7 generated from WT 
mice were incubated for 48 hours in the presence of histamine 1 µM and 0.1% (V/V) DMSO and JNJ 
7777120 1 µM with or without LPS 100 ng/ml. NO concentrations were measured in the supernatant. 
The experiments were performed in duplicate and data show means ± SD from one of two 
independent experiments. P value was calculated with two-way ANOVA test. 
 
3.3.7. Comparison of WT mice and H4R -/- mice in an experimental 
model of Leishmaniasis  
 In order to assess the physiological relevance of the previous data, 
Leishmaniasis was considered as a suitable model to challenge the H4R -/- mice. As 
previously mentioned, TH1 immune response is the key factor in the mouse immunity 
against L. major. This includes macrophage phagocytosis, production of pro-
inflammatory cytokines as well as NO production. However, as it is already 
mentioned in the Introduction, C57BL/6 mice are resistant against Leishmania 
infection. In these mice the infection develops relatively slowly, and the mice recover 
from the infection after 8-9 weeks. Conversely, Leishmaniasis in BALB/c mice is a 
lethal infection because of the impaired TH1 response in this strain [129;130].  
 Therefore, a high dose Leishmania infection in WT and H4R -/- mice (n = 3 per 
group) was generated by injecting subcutaneously 3x106 L. major promastigotes in 
the right foot. Thickness of both feet was measured every week after infection, and 
calculated relative to the non-infected foot. 
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H4R -/- mice show a similar swelling pattern to the control mice with a general higher 
swelling level especially 2-3 weeks after the infection (Fig. 3.35), indicating that the 
absence of mH4R from the immune cells has a moderate effect on the immunity 
against L. major. 
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Fig. 3.35: Footpad swelling after L. major infection. H4R -/- show a higher footpad swelling curve 
during Leishmaniasis than WT in high dose infection. Data show means ± SD. 
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3.4. Mouse anti-mH4R antibody generation 
 
3.4.1. Testing the commercially available antibodies in Western-blot 
 In order to validate the previously shown data of mH4R expression on the 
mRNA level, and show the expression of mH4R on the protein level, commercial 
antibody was used to perform western-blot with cells which express H4R on the 
mRNA level by RT-PCR. 
Western-blot was performed with the protein lysate of the different cells (see 3.3.1) in 
addition to BMDC day 8 (immature BMDC) and HEK-293 cells. The western blot 
results show that the commercial antibody had recognized non-specific antigens with 
molecular weights lower and higher than the expected mH4R band (Fig. 3.36). Based 
on unpublished data, the molecular weight of mH4R was detected at around 45 kD 
when tagged with V5 antigen. Due to the non-specificity of these antibodies no 
further experiments were performed with them.   
 
 
 
 
Fig. 3.36: Unspecific bands appeared in Western-blot with the commercial antibodies. Protein 
lysate from cell lines were examined by western-blot using commercial antibody from Santa-Cruz ®.  
 
3.4.2. Immunizing H4R -/- mice against two peptides from mH4R  
 Based on the previous finding, the next aim was to generate mouse anti-mH4R 
antibodies using the H4R -/- mice. These mice can be immunized against the whole 
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mH4R or part of the receptor because they lack the protein and can develop 
antibodies without affecting any self-antigen.  
 Therefore, two synthesized peptides (see 2.1.12) the first is the second extra-
cellular domain (2nd-ECD), and the second peptide is the third extra-cellular domain 
(3rd-ECD) were used for immunization (see 2.2.5.1.). The approach behind using the 
extracellular peptides is to future use of the generated antibodies in immuno-assays 
such as FACS and fluorescent microscopy without the need to permeabilizing the 
cells and with the possibility of using the antibodies to test them for agonistic or 
antagonistic effects on the receptor.   
 
3.4.3. Screening the antibody production in the serum of immunized 
mice 
 Antibody production was tested in mice sera before immunization and after 
each boost. The ELISA assay was used to determine the serum antibody titers 
against the respective peptide coupled to BSA instead of KLH to avoid the 
unspecificity (see 2.2.5.3.). Serum titer was determined as serum dilution with double 
O.D value than the negative control. ELISA results show that both mice produced 
antibodies against both peptides after the first boost (Fig. 3.37.A) with a better serum 
titer in the mouse immunized against 3rd-ECD (12800) than the mouse immunized 
against 2nd-ECD (3200). After the second boost (Fig. 3.37.B) both sera showed 
enhanced titers (25500) and (6400) respectively.    
 
 
 
 
 
3. Results 
 
87 
after the first boost
0
0,5
1
1,5
2
2,5
3
3,5
1:1
00
1:2
00
1:4
00
1:8
00
1:1
60
0
1:3
20
0
1:6
40
0
1:1
28
00
1:2
56
00
1:5
12
00
1:1
02
40
0
Bl
an
k
serum dilution
O
.
D
.
anti-2nd ECD
anti-3rd ECD
after the second boost
0
0,5
1
1,5
2
2,5
3
3,5
4
1:1
00
1:2
00
1:4
00
1:8
00
1:1
60
0
1:3
20
0
1:6
40
0
1:1
28
00
1:2
56
00
1:5
12
00
pre
-
se
ru
m
Bla
nk
serum dilution
O
.
D.
anti-2nd ECD
anti-3rd ECD
A B
.
.
.
.
.
.
.
.
O
.
D
.
O
.
D.
O
.
D
.
O
.
D.
 
 
Fig. 3.37: Antibody production in mouse sera. ELISA test was used to determine the antibody 
production and titers after the first (A) and the second boost (B). ELISA test was performed with BSA-
coupled peptides in 96 well plate as triplicate, the blank values were obtained from wells without 
serum. Values represent mean and standard deviations.    
3.4.4. Western-blot using immunized mice serum 
 The two sera (after second boost) were used in a Western-blot experiment 
with protein lysates from cells expressing H4R on the mRNA level (bone marrow and 
BMDM) as well as Sf9 cells infected with Baculovirus containing mH4R in an 
expressing vector. As negative control, a protein lysate was used from bone marrow, 
BMDM from H4R -/- mice, and Sf9 cells infected with Baculovirus containing an empty 
vector. Serum containing anti-2nd-ECD did not show any band, whereas serum 
containing anti-3rd-ECD (Fig. 3.39) showed some unspecific bands in both positive 
and negative cells, indicating that sera from these immunized mice could not be 
directly used to detect mH4R expression on the protein level. 
 However, the successful immunization as detected by ELISA (Fig. 3.37.) gives 
the chance to generate monoclonal antibodies from plasma cells residing in the 
spleen. Therefore, both spleens were isolated and frozen three days after the second 
boost in liquid nitrogen for further experiments.  
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Fig. 3.38: Testing the anti-serum in western-blot. The anti serum from the mouse after the second 
boost (anti-3rd ECD) was used in western-blot. Non-specific binding was observed indicating that the 
serum is not suitable for the determination of mH4R in this assay. 
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4. Discussion  
 
  
 In order to elucidate the biological role of H4R in a mouse model, it was 
essential to focus on one cellular model. Therefore, the main part of the work was 
analysing the expression H4R in several immune cells, and determination of a 
suitable cellular model. The regulation of H4R was a crucial point on the way to 
understand the mechanism by which H4R modulates immune mechanisms. 
Therefore, mouse macrophages as a cellular model to study the functions of H4R, 
were analyzed in functional assays upon H4R stimulation or inhibition. Moreover,   
H4R -/- mice represented a valuable tool in order to compare macrophages in the 
presence or absence of H4R, and the effect of H4R on their immune functions. 
 Furthermore, the absence of suitable commercial antibodies against mH4R 
has imposed the generation of antibodies against H4R, as an additional goal of this 
work. Such antibodies could be used in the determination and quantification of H4R 
on the protein level.  
 
4.1 H4R and DC 
 
 H4R is predominantly expressed in haematopoietic immune cells. Further 
reports revealed that other cells and tissues show also a detectable expression level 
of the receptor [34]. Among the haematopoietic immune cells, DC as key cells 
relating the innate and adaptive immunity were shown to express H4R as well as 
other histamine receptors in human and mouse [49;63-65].  
 In the early stages of this work, no clear H4R expression had been shown in 
mouse DC. Therefore, BMDC were used to examine theses cells. BMDC generation 
represents a suitable tool to generate sufficient number of immature DC in vitro. 
These cells are functional DC with the ability of presenting antigen to T cells and 
activate them. The supernatant of X6310 cells is an appropriate source of GM-CSF, 
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the essential growth factor for bone marrow cell differentiation to DC. This was 
confirmed by the expression of CD11c on the cells, and the expression of CD86 and 
MHC II upon LPS stimulation, which confirmed that the generated DC have the main 
DC markers [133].     
 The expression of H4 as well as H1 and H2 receptors was detected on the 
mRNA level, in both mature and immature BMDC, as well as in bone marrow cells. 
These data were confirmed later by several publications in which a functional 
expression of H4R in human and mouse DC was observed, claiming a role of H4R in 
DC chemotactic activity. Another report has observed the expression of H3R in 
addition to H1, H2 and H4R in DC [65]. Furthermore, the regulation of mH4R during 
bone marrow differentiation to DC and DC maturation with LPS was investigated by 
real-time PCR. The continuous down-regulation of mH4R during differentiation and 
maturation may hint at the role of H4R role in both processes.  
 The BMDC maturation state represented by the expression of CD86 and   
MHC II on CD11c+ cells did not show any change upon histamine or 4MEH 
stimulation, indicating that H4R did not play any direct role in the maturation process. 
Similarly, a report from Pavlinkova et al. in 2003, H1R and H2R were down-regulated 
after LPS or TNF stimulation of immature BMDC from BALB/c mice. Furthermore, 
histamine did not modulate the expression of CD86 on stimulated BMDC. From the 
same report, histamine slightly up-regulates IL-12p40 production from immature 
BMDC, in a dose response manner, claiming a role in BMDC maturation [138]. 
Different results were reported by Guzmer at al. in 2005 showing that H4R stimulation 
dowregulates IL-12p70 from human DC [64]. In 2001, Caron et al. showed that 
histamine induces CD86 expression and IL-8 production from human monocyte-
derived DC. The effect was inhibited by preincubation with H1 or H2 receptor 
antagonists, but not in thioperamide-treated cells, but the authors mentioned that 
histamine-stimulated DC did not have the phenotype of fully mature DC [67]. The 
previous contradictory data are possibly due to the differences between human and 
mouse cells, and the different protocols used to generate human DC. Another factor 
that could interfere in the results is the FCS used as a supplementary medium in cell 
culture. In general, FCS contains a variable amount of LPS traces depending on the 
provider and sometimes even on the batches from the same provider. These LPS 
contamination varies between very low amounts and higher levels which could be 
sufficient to stimulate the cells, especially APC such as DC and macrophages. 
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Therefore, and based on the down-regulation of mH4R upon LPS stimulation as 
mentioned in Fig 3.4 - 3.5, LPS levels in the medium have to be controlled.   
 Histamine production and its autocrine effect on mouse DC was reported 
previously in both, human and mouse cells [65;69]. Therefore, the role of histamine in 
DC maturation had to be studied considering that histamine is secreted in the 
medium from the cells. This amount of histamine produced from immune cells is 
lower than mast cell-derived histamine, and these cells might not respond to the 
additional amounts of histamine. Therefore, the low expression level of H4R in mature 
BMDC might be a physiological response to the histamine produced in medium, in 
order to minimize the autocrine effect. This, in addition to the relatively high affinity of 
H4R for histamine are reasons to speculate about a role of H4R in the autocrine effect 
of histamine in DC [61;62;139-141].  
 
4.2. H4R and T lymphocytes  
 The expression of H4R on the mRNA level in human spleen and lymph node 
cells was reported in earlier publications simultaneously with the discovery of H4R 
[142;143]. In the mouse model, Hofstra et al. from the Johnson and Johnson 
research group has mentioned in 2002 that H4R is exclusively expressed in mast 
cells and eosinophils. In addition, no detectable expression was found in spleen, 
lymph nodes, CD4+, CD8+ T cells, B cells or macrophages [73]. From the same 
research group and three years later, Dunford et al. reported that H4R on CD4+ T 
cells modulate the immune response during asthma development [69]. Additional 
reports claimed a functional expression of mH4R in T cells, without showing the 
expression neither on mRNA nor protein levels. Therefore, the expression of H4R in 
the previously mentioned immune organs and cells was important to investigate the 
role of H4R. The expression of mH4R in spleen and axillary lymph nodes found in this 
work was similar to the human data mentioned before. Notably, the total amount of 
RNA in spleen and lymph nodes as secondary lymphatic organs mainly consisted of 
RNA from T and B cells in addition to antigen presenting cells (DC, macrophages). 
The expression of H4R in CD4+, CD8+ T cells sorted from spleen, as well as DC and 
macrophages can explain the previous data of positive H4R in spleen and lymph 
nodes. The negative expression of H4R in B cells confirms the literature data where 
no expression or role of H4R in B cells has been reported.  
4. Discussion 
 
 
92 
 HDC activity in T cells and histamine production was also reported by several 
reports. Therefore, histamine must be considered as an important factor in any 
research regarding H4R effect on T cells [4;5;144].  
 As a conclusion, the expression of H4R in all the previously mentioned organs 
and cells adds evidence to the role of H4R as an immune modulator, since all the 
immune cells in their general definition except B cells express H4R. 
 
4.3. H4R and macrophages 
4.3.1. Expression and regulation 
 The successful differentiation of bone marrow cells to macrophages using 
L929 supernatant medium as a source of M-CSF indicates that this method is 
appropriate with low costs to generate inactivated macrophages in vitro. In order to 
control the concentration of M-CSF in medium recombinant M-CSF can also be used 
for differentiation. The generated macrophages express the main surface markers for 
mouse macrophages, without expression of IL-6 or TNF indicating that the generated 
cells are not activated. Macrophage activation can be encountered due to several 
factors such as contamination, cell culture medium or type of dishes. Moreover, these 
cells are similar to fully functional macrophages with respect to their capability of 
chemotaxis, phagocytosis, pro-inflammatory cytokines production, and IL-10 
production as an anti-inflammatory cytokine (data not shown). The cell culture 
techniques and materials used especially the square dishes used for the BMDM 
generation are very essential factors in order to obtain functionally intact cells. 
Previous protocols used cell adherence as an essential step to generate BMDM, but 
detaching the cells without damaging them remains an important factor. In this term, 
the cells were sometimes generated in Teflon-coated cell culture dishes or even in 
Falcon® tubes and the very marginally attached cells were harvested by gently 
aspiring the medium [136;145]. In the method used in this work, the macrophages 
generated in Sterilin square Petri dishes were slightly attached to the bottom, and the 
gentle scraping of the cells did not cause any remarkable damage or activation effect 
like IL-6 production (data not shown). Unfortunately, no clear information was 
available about coating materials used in those dishes from the provider.     
 Peritoneal macrophages are the most commonly used primary mouse 
macrophages. In order to isolate a fair number of cells, sub-inflammation state has to 
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be induced prior to the cell harvest. This manipulation leads to more macrophages 
migrating to the inflamed site and increasing the yield of the elicited cells. Several 
methods were used in this respect, such as injecting PBS, thioglycolate or protease 
peptone into the mouse peritoneum for different lengths of time. The activation state 
of elicited-macrophages varies depending on the injected substances and the time. 
Sterile PBS injection for 14 h is considered as the least activating material, although it 
is known that the harvested cells are slightly activated [146]. The percentage of 
macrophages in the harvested cells can also differ according to the method, but in all 
methods the majority of the adherent cells are mouse macrophages as shown in Fig. 
3.11.   
 Other macrophage types used in this work are macrophage cell lines RAW 
264.7 and J774.1. These cells were used at the early stages of this work to screen 
the expression of H4R in several cell lines. High passage numbers were avoided in 
RAW 264.7 cells because the cells showed some morphological abnormalities 
associated with low expression level of H1 and H4 receptors in RT-PCR (data not 
shown). Therefore, those cells were replaced every 8-10 weeks with a new aliquot 
from liquid nitrogen frozen cells. 
 The similar HR expression pattern in all the previous macrophage types 
indicates and validates the fact that mH4R is expressed in mouse macrophages on 
the mRNA level. Until now no data have been reported on positive expression of H4R 
in mouse macrophages, while one report in 2002 mentioned that only mouse mast 
cells and eosinophils express H4R but no other immune cells [73]. This novel finding 
in the mouse system was confirmed by two reports about human monocytes which 
are the closest cells to macrophages on the differentiation level [48;49].  
 The regulation of mH4R in response to different stimuli in RAW 264.7 and 
BMDM cells showed a similar response to IFN-γ, demonstrated by significantly up-
regulation of mH4R expression. Moreover, RAW 264.7 cells up-regulated mH4R in 
response to IFN-α and TNF within 6 hours upon stimulation, whereas longer 
exposure to these stimuli down-regulated mH4R. Similar results reported by Dijkstra 
et al. in 2007 revealed that human monocytes up-regulate the expression of H4R 
upon IFN-γ stimulation as well as in combination with TNF [48]. In-silico inspection of 
potential transcription factors in the promoters of human and mouse H4R gives a 
possible explanation of mH4R up-regulation upon interferon stimulation. Notably, 
several potential binding sites of Interferon-stimulated response element (ISRE also 
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known as Interferon regulatory factors IRF-7) exist in both promoters. According to 
the same report, NFκB potential binding sites exist also in the promoter region, this 
can also explain the mechanism by which LPS and TNF influence the gene 
expression. The sequence alignment between mouse and human H4R promoters 
shows in addition to the previous transcription factors, that binding sites for GATA-1, 
3 and STAT-5 potentially exist in the both promoters. These transcription factors are 
essential in the development of haematopoietic cells (data not shown) [143].  
 BMDM showed in a similar manner as BMDC lower mH4R expression than 
bone marrow cells. This can also indicate the similarities between both cell types 
since both are APC and share a long list of common functions (e.g. cytokine 
production and tissue distribution). Similar to the findings in BMDC, mH4R expression 
was down-regulated upon LPS activation, indicating that LPS-activated BMDM 
express a very low levels of mH4R after 24 h. Interestingly, in a report about human 
macrophages, Laszlo et al. in 2001 reported a higher HDC activity in LPS-activated 
macrophages, suggesting that these cells produce histamine [59]. Therefore, and 
similar to the BMDC speculation the down-regulation of mH4R in response to LPS 
can be a physiological response to reduce the effect of the self-produced histamine 
on the cells. 
 
4.3.2. Chemotaxis response 
 In this respect the first question to answer was to find a possible role of mH4R 
in mouse macrophages. At the time being, most of the known functions of H4R in 
general were induction of chemotaxis in eosinophils, mast cells and DC. Thus, 
chemotactic activity of BMDM in response to mH4R stimulation was investigated. 
Therefore, and in order to minimize the effect of histamine on H1 and H2 receptors, 
4MEH was used instead of histamine to activate mH4R. As previously mentioned, 
4MEH, the selective H4R agonist, shows an agonistic activity on H2R but with more 
than 100-fold higher EC50 value than H4R. 4MEH shows also some activity when 
binding to H1R but only in higher concentrations than H2R [19].  
 BMDM migrated towards 4MEH in a dose-response manner. The curve 
number of migrated cells revealed a bell shape in between 1 nM and 10 µM on a 
logarithmic scale, with the highest peak at 100 nM. However, the curve also revealed 
a non-typical shape by a significant migration towards 100 µM. The fact that 4MEH is 
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also an H2R agonist can explain the second peak, although in a previous report from 
1975 high histamine concentrations inhibited histamine-induced chemotaxis via H2R 
activation in human eosinophils [147].  
 Histamine-induced chemotaxis was reported in human monocytes (THP-1 
clone 15 cell line) by Damaj et al. in 2007. The cells responded in a dose response 
manner to the histamine concentrations with the highest peak at 10-100 nM, without 
showing the second peak [49]. The inhibition of 4MEH-induced (up 1 µM) chemotaxis 
by pre-incubating the cells with 1 µM of JNJ 7777120, and the migration of cells 
towards 10 and 100 µM indicate that the second peak is mediated by another 
receptor than H4R. Furthermore, blocking H1 and H2 receptors separately did not 
influence the migration towards 100 nM of 4MEH, whereas only JNJ 7777120 
inhibited migration. This migration in the presence of JNJ 7777120 towards fMLP or 
the high concentrations of 4MEH indicated that the chemotaxis machinery was not 
inhibited due to cytotoxicity of this compound. Based on the previous finding, it can 
be concluded that mH4R mediates a chemotactic effect in response to 4MEH. As an 
additional confirmation of the previous results, H4R -/- BMDM did not migrate towards 
100 nM of 4MEH, whereas the cells migrated in the presence of 100 µM of 4MEH. 
The receptor mediating the 100 µM migration remains unknown. This novel role of 
mH4R in mouse macrophages revealed that H4R is a chemotactic mediator in a 
variety of immune cells in both human and mouse.  
 
4.3.3. Comparing BMDM from WT and H4R -/- mice 
4.3.3.1. BMDM differentiation 
 The first step in the comparison concerned the expression of the macrophage 
markers. This step was essential to examine the capability of bone marrow cells to 
differentiate to macrophages in the absence of mH4R. Unexpectedly, higher numbers 
of CD11b+ and F4/80+ cells were observed in H4R -/- cells indicating that these cells 
generated more macrophages than WT cells. The exact mechanism could not be 
elucidated. Notably, the percentages of macrophages slightly differed between 
several experiments, possibly because of the variation in M-CSF concentrations in 
medium. However, the fact that WT and H4R -/- cells were differentiated in the same 
medium in each experiment revealed that the differentiation mechanism is affected 
by the absence of mH4R. The difference between WT and H4R -/- was lower when the 
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macrophage percentage was high (over 90%), whereas lower macrophage 
percentages in culture (around 80%) showed a clearer difference between the two 
mouse types. No morphological differences were observed between both types under 
the microscope, nor in FACS analyze when comparing cell size (forward scatter FSC) 
and granulation (sideward scatter SSC) (data not shown). The fact that precursor 
macrophages express higher HDC in response to M-CSF suggests that histamine is 
present during the differentiation from bone marrow cells to macrophages. These 
findings support the previous hypothesis about an autocrine effect of histamine 
through H4R on the immune cells [59].      
 
4.3.3.2. Phagocytosis 
 The previous surprising finding urged another question about the functionality 
of these macrophages. Surprisingly, phagocytosis as one of the main macrophage 
functions appeared to be affected in H4R -/- BMDM. This was shown by a significantly 
lower capability of ingesting FITC-microbeads. This was not due to any 
morphological variations between the cells, since both macrophage types were 
similar in size and granulation levels.  
 In order to validate the BMDM findings, the phagocytosis had to be inspected 
in peritoneal macrophages from H4R -/- mice. The isolation of peritoneal macrophages 
is always associated with non-macrophage immune cells such as neutrophils and 
other granulocytes up to certain levels depending on the method as mentioned 
before. These cells have the capability to also phagocytose the FITC-microbeads. 
Therefore, the role of these cells had to be excluded by staining the macrophages 
with anti-F4/80-labelled antibodies, and analyze the phagocytosis in the F4/80+ cells 
only. Similar to BMDM data, the cells from H4R -/- showed lower phagocytic activity, 
which revealed that not only the cells generated in vitro but also primary cells were 
affected by the absence of mH4R.  
 The fact that L. major lives in macrophages, as a part of the pathophysiology 
of Leishmaniasis, raised the question about the phagocytic activity in this model. 
Therefore, BMDM from both mouse types were challenged with CFSE-labelled L. 
major promastigotes in phagocytosis. The difference was similar to the results 
obtained from the previous two phagocytosis models.  
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 It was recently reported that stimulation of H4R in human TH2 cells and DC 
leads to induction of activator protein-1 (AP-1) signal transduction. This transcription 
factor is modulating a wide range of genes including several cytokines in the immune 
system such as IL-4, IL-5 and IL-13 [148-150]. As previously mentioned, H4R 
stimulation leads to MAPK activation. These MAPKs induce the expression of AP-1 
family transcription factors such as Fos and Jun and activate the transcriptional 
activity of AP-1 proteins by phosphorylation of their transcription activation domains. 
Moreover, AP-1 was also reported as an important transcription factor in immune 
cells and bone formation [151;152]. The previous point could give a hint at the 
mechanism in which H4R modulates the immune response.  
 Surprisingly, histamine as a biological ligand of H4R did not show any 
induction of phagocytic activity in BMDM, this gave rise to the hypothesis about 
potential self-produced histamine and its autocrine effect on the whole mechanism, 
which means that the cells produce the necessary amount of histamine and the 
additional histamine is not capable to induce phagocytosis to a higher level. To proof 
this point a phagocytosis assay was performed in the presence of several 
concentrations of JNJ 7777120. However, the results revealed that blocking mH4R 
during the phagocytosis assay did not influence the BMDM phagocytic activity. This 
speaks against the hypothesis about any role of self-produced histamine in 
phagocytosis, but does not answer the question about a possible role of histamine 
during BMDM differentiation.  
 To answer this question, BMDM generated in the presence of JNJ 7777120 
were compared to WT-BMDM and H4R -/- BMDM. In this model the cells generated in 
the presence of JNJ 7777120 showed a lower phagocytic activity compared to WT-
BMDM and similar to H4R -/- BMDM, but the percentage of macrophages were also 
lower than WT-BMDM unlike H4R -/- BMDM. The interpretation of these results could 
be that JNJ 7777120 partially inhibited bone marrow differentiation to macrophages. 
The exact effect of JNJ 7777120 on bone marrow differentiation has to be further 
investigated.  
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4.3.3.3. TNF, IL-6 and NO production 
 
 In order to examine other macrophage functions of H4R -/- BMDM, the 
capability of pro-inflammatory cytokine production was examined in comparison to 
WT-BMDM. Therefore, IL-6 and TNF production was determined in the supernatant 
of LPS activated cells, and NO was measured upon LPS and IFN-γ activation. Similar 
to the phagocytosis results, IL-6, TNF and NO production was partially inhibited in the 
H4R -/- BMDM. Based on these results, the effect of histamine on the production of 
previous parameters was examined. Similar results were observed with no direct 
effect of histamine on the production of IL-6, TNF and NO in BMDM. Histamine as an 
inducer of IL-6 production from human lung macrophages was mentioned in a single 
report, with no other evidence of a histamine role in macrophage activation [55].  
 
4.3.3.5. Hypothesis to explain the H4R effect   
 The mechanism by which the absence of H4R influences macrophage 
functions whereas histamine did not show any effect, induced a speculation of three 
possible mechanisms (Fig. 4.1).  
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Fig. 4.1: Possible mechanisms of H4R effect in macrophages. A: mH4R has a constitutive activity 
in which histamine is not necessary to keep the basal activity. B: Another ligand than histamine is 
produced by macrophages and plays a role in an autocrine manner via mH4R. C: Histamine is 
produced from bone marrow cells and can act as an autocrine stimulator, which is important to 
generate fully active macrophages.   
 
 In the first potential mechanism, the H4R is constitutively active in the absence 
of histamine. Such a constitutive activity of HR has been reported in all human 
receptors but no clear proof of any constitutive activity in the mouse model has been 
obtained so far. However, based on unpublished data from a colleague (David 
Schnell, PhD thesis), no constitutive activity of the mH4R was observed when the 
receptor activity was measured in the GTPase assay. In the second hypothesis, 
macrophages can produce another ligand to mH4R e.g. a chemokine that can bind to 
the receptor and induce the functions. In this respect, the ability of CCL16 to bind to 
human H4R and induce chemotaxis was reported in one publication without any 
further reports supporting or denying it [34;153]. However, no analogue of the human 
CCL16 has been documented in the mouse system up till now. The third hypothesis 
speculates that histamine plays a role in bone marrow differentiation to macrophages 
in an autocrine manner through mH4R. This suggests that the expression of mH4R on 
bone marrow cells is necessary to differentiate the cells to the normal macrophages. 
This hypothesis is supported by the higher expression level of mH4R found in bone 
marrow cells than in macrophages. Moreover, it was reported that precursor 
macrophages express high level of HDC when stimulated with M-CSF, suggesting 
that these cells produce histamine in the presence of M-CSF [59;154;155].  
4. Discussion 
 
 
100 
4.3.4. The role of mH4R in Leishmaniasis  
 In order to examine the effect of mH4R on the immune system and validate the 
previous findings in macrophages, Leishmaniasis was analyzed in WT and H4R -/- 
mice. The footpad swelling in both mouse strains showed the typical swelling pattern 
of C57BL/6 mice, where the highest swelling point was observed within three weeks 
followed by diminution of the swelling, later on the curve showed another lower peak 
before the footpad regained the normal size. In general, higher footpad swelling 
levels in H4R -/- mice were observed in comparison to WT, especially within the first 
three weeks. This higher swelling level did not affect the development of the disease, 
indicating that the effect of mH4R did not play an important role in the immunity 
against Leishmaniasis.  
 
4.4. The generation of antibodies against mH4R 
 With the aim of detecting the expression of mH4R on the protein level, 
commercially available polyclonal antibodies were tested in western-blot analysis. 
The cell protein lysates used in the assay were validated by RT-PCR, and showed a 
positive expression of mH4R. Surprisingly, these antibodies did not recognize any 
protein of the expected molecular weight of mH4R, however some other unspecific 
bands were observed, indicating that no further experiments could be performed with 
these antibodies.  
 The first attempt to generate antibodies against mH4R was performed in 
rabbits to generate polyclonal antibodies (data not shown). The rabbits sera as well 
as the purified IgG antibodies from the rabbits sera showed non-specific binding in 
western-blot. In another attempt, H4R -/- mice were used to generate mouse anti-
mH4R. As previously mentioned, the mouse system is mainly used to generate 
monoclonal antibodies, because of the limited volume of serum that can be obtained 
from mice. The ELISA screening results revealed that the immunization was 
successful and both mice generated antibodies in their serum against the injected 
peptides. As expected, the boost increased titers in the immunized mice. 
Unfortunately, the mouse sera did not appear to be a good source of antibodies 
when tested in western-blot, because only non-specific bands were obtained when 
cells from WT and H4R -/- mice were used. The antibodies seemed to recognize only 
the peptides but not the native receptor on the cells. One of the possible reasons of 
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the negative results is the glycosylation of the second and third extracellular domains 
in the native receptor, which might inhibit the antibody recognition. Another possible 
reason is the protein 3D structure, where the antibodies could not recognize their 
epitopes due to the inaccessibility. The protein lysates were treated under reductive 
conditions with β-meracptoethanol and dithiothreitol (DTT) separately at high 
temperature, which cleaves the disulphide bridges in proteins and unfolds the protein 
structure. The non-specificity of produced antibodies against other GPCRs is a 
commonly encountered problem as discussed by Michel et al. and Gupta et al 
[156;157]. However, generation of monoclonal antibodies using the spleens of the 
immunized mice could be a promising to generate a specific tool for mouse H4R 
research. 
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Summary  
 
  
 Several reports have identified the H4R as an important receptor in 
inflammatory mechanisms and thus, as a therapeutic target for several diseases. The 
focus of this work was to identify and further characterize the role of mH4R on mouse 
myeloid immune cells. 
 
 A novel finding of this thesis is the expression of mH4R in DC macrophages, 
and T cells (CD4+, CD8+) which was determined on the mRNA level. The expression 
was down-regulated during bone marrow differentiation to BMDC as well as to 
BMDM, and both cell types expressed lower mH4R levels when stimulated by LPS, 
but IFN-γ seemed to be an inducer of mH4R expression.  
 
 A novel function of mH4R is the chemotactic effect on BMDM in response to 
4MEH. This finding supported other findings from human and mouse cells. In the 
functional analysis, histamine was found not to have any direct effect on BMDM 
functions such as phagocytosis, TNF, IL-6 and NO production. Conversely, the 
absence of the mH4R on macrophages revealed a partial functional defect in 
phagocytosis and the production of cytokine. These findings indicate a possible role 
of mH4R in bone marrow differentiation to macrophages.  
 
 Based on the findings in this thesis several topics should be further 
investigated, and the exact role of mH4R on myeloid cells should be analyzed on the 
molecular level with the advantage of the H4R -/- mice.    
 
   
 
 
Reference List 
 
 
103 
Reference List 
 
 
 1.  Akdis CA and Simons FE, Histamine receptors are hot in immunopharmacology. 
Eur.J.Pharmacol. 533: 69-76, 2006. 
 2.  Maintz L and Novak N, Histamine and histamine intolerance. Am.J.Clin.Nutr. 85: 1185-1196, 
2007. 
 3.  Parsons ME and Ganellin CR, Histamine and its receptors. Br.J.Pharmacol. 147 Suppl 1: 
S127-S135, 2006. 
 4.  Kubo Y and Nakano K, Regulation of histamine synthesis in mouse CD4+ and CD8+ T 
lymphocytes. Inflamm.Res. 48: 149-153, 1999. 
 5.  Jutel M, Blaser K, and Akdis CA, The role of histamine in regulation of immune responses. 
Chem.Immunol.Allergy 91: 174-187, 2006. 
 6.  Kawaguchi-Nagata K, Okamura H, Tamura T, Yamatodani A, Watanabe T, Wada H, Taguchi 
T, Kitamura Y, and Shoji K, Induction of histidine decarboxylase activity in the spleen of mice 
treated with staphylococcal enterotoxin A and demonstration of its non-mast cell origin. 
Biochem.Biophys.Res.Commun. 129: 187-192, 1985. 
 7.  Schwelberger HG and Bodner E, Purification and characterization of diamine oxidase from 
porcine kidney and intestine. Biochim.Biophys.Acta 1340: 152-164, 1997. 
 8.  Schwelberger HG, Hittmair A, and Kohlwein SD, Analysis of tissue and subcellular localization 
of mammalian diamine oxidase by confocal laser scanning fluorescence microscopy. 
Inflamm.Res. 47 Suppl 1: S60-S61, 1998. 
 9.  Klocker J, Matzler SA, Huetz GN, Drasche A, Kolbitsch C, and Schwelberger HG, Expression 
of histamine degrading enzymes in porcine tissues. Inflamm.Res. 54 Suppl 1: S54-S57, 2005. 
 10.  Yamauchi K, Sekizawa K, Suzuki H, Nakazawa H, Ohkawara Y, Katayose D, Ohtsu H, 
Tamura G, Shibahara S, Takemura M, and ., Structure and function of human histamine N-
methyltransferase: critical enzyme in histamine metabolism in airway. Am.J.Physiol 267: L342-
L349, 1994. 
 11.  Kuefner MA, Schwelberger HG, Weidenhiller M, Hahn EG, and Raithel M, Both catabolic 
pathways of histamine via histamine-N-methyltransferase and diamine oxidase are diminished 
in the colonic mucosa of patients with food allergy. Inflamm.Res. 53 Suppl 1: S31-S32, 2004. 
 12.  Raithel M, Kufner M, Ulrich P, and Hahn EG, The involvement of the histamine degradation 
pathway by diamine oxidase in manifest gastrointestinal allergies. Inflamm.Res. 48 Suppl 1: 
S75-S76, 1999. 
Reference List 
 
 
104 
 13.  Hough LB, Genomics meets histamine receptors: new subtypes, new receptors. 
Mol.Pharmacol. 59: 415-419, 2001. 
  14.  Liu C, Wilson SJ, Kuei C, and Lovenberg TW, Comparison of human, mouse, rat, and guinea 
pig histamine H4 receptors reveals substantial pharmacological species variation. 
J.Pharmacol.Exp.Ther. 299: 121-130, 2001.
 
 15.  Nakamura T, Itadani H, Hidaka Y, Ohta M, and Tanaka K, Molecular cloning and 
characterization of a new human histamine receptor, HH4R. Biochem.Biophys.Res.Commun. 
279: 615-620, 2000. 
 16.  Oda T, Morikawa N, Saito Y, Masuho Y, and Matsumoto S, Molecular cloning and 
characterization of a novel type of histamine receptor preferentially expressed in leukocytes. 
J.Biol.Chem. 275: 36781-36786, 2000. 
 17.  Jablonowski JA, Grice CA, Chai W, Dvorak CA, Venable JD, Kwok AK, Ly KS, Wei J, Baker 
SM, Desai PJ, Jiang W, Wilson SJ, Thurmond RL, Karlsson L, Edwards JP, Lovenberg TW, 
and Carruthers NI, The first potent and selective non-imidazole human histamine H4 receptor 
antagonists. J.Med.Chem. 46: 3957-3960, 2003. 
 18.  Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley 
JP, Sun S, Williams KN, Edwards JP, and Karlsson L, A potent and selective histamine H4 
receptor antagonist with anti-inflammatory properties. J.Pharmacol.Exp.Ther. 309: 404-413, 
2004. 
 19.  Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, and Leurs R, Evaluation of histamine 
H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-
methylhistamine as the first potent and selective H4 receptor agonist. J.Pharmacol.Exp.Ther. 
314: 1310-1321, 2005. 
 20.  Ohki E, Suzuki M, Aoe T, Ikawa Y, Negishi E, and Ueno K, Expression of histamine H4 
receptor in synovial cells from rheumatoid arthritic patients. Biol.Pharm.Bull. 30: 2217-2220, 
2007. 
 21.  Schneider EH, Schnell D, Papa D, and Seifert R, High Constitutive Activity and a G-Protein-
Independent High-Affinity State of the Human Histamine H(4)-Receptor (dagger). 
Biochemistry, 2009. 
 22.  Varga C, Horvath K, Berko A, Thurmond RL, Dunford PJ, and Whittle BJ, Inhibitory effects of 
histamine H4 receptor antagonists on experimental colitis in the rat. Eur.J.Pharmacol. 522: 
130-138, 2005. 
 23.  Gutzmer R, Mommert S, Gschwandtner M, Zwingmann K, Stark H, and Werfel T, The 
histamine H4 receptor is functionally expressed on T(H)2 cells. J.Allergy Clin.Immunol. 123: 
619-625, 2009. 
 24.  Connelly WM, Shenton FC, Lethbridge N, Leurs R, Waldvogel HJ, Faull RL, Lees G, and 
Chazot PL, The histamine H4 receptor is functionally expressed on neurons in the mammalian 
CNS. Br.J.Pharmacol. 157: 55-63, 2009. 
 25.  Cowart MD, Altenbach RJ, Liu H, Hsieh GC, Drizin I, Milicic I, Miller TR, Witte DG, Wishart N, 
Fix-Stenzel SR, McPherson MJ, Adair RM, Wetter JM, Bettencourt BM, Marsh KC, Sullivan 
JP, Honore P, Esbenshade TA, and Brioni JD, Rotationally constrained 2,4-diamino-5,6-
disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved 
Reference List 
 
 
105 
druglikeness and in vivo efficacy in pain and inflammation models. J.Med.Chem. 51: 6547-
6557, 2008. 
 26.  Leurs R, Chazot PL, Shenton FC, Lim HD, and de Esch IJ, Molecular and biochemical 
pharmacology of the histamine H4 receptor. Br.J.Pharmacol. 157: 14-23, 2009. 
 27.  Lim HD, Adami M, Guaita E, Werfel T, Smits RA, de Esch IJ, Bakker RA, Gutzmer R, Coruzzi 
G, and Leurs R, Pharmacological characterization of the new histamine H4 receptor agonist 
VUF 8430. Br.J.Pharmacol. 157: 34-43, 2009. 
 28.  Smit MJ, Leurs R, Alewijnse AE, Blauw J, Nieuw Amerongen GP, Van D, V, Roovers E, and 
Timmerman H, Inverse agonism of histamine H2 antagonist accounts for upregulation of 
spontaneously active histamine H2 receptors. Proc.Natl.Acad.Sci.U.S.A 93: 6802-6807, 1996. 
 29.  Smits RA, de Esch IJ, Zuiderveld OP, Broeker J, Sansuk K, Guaita E, Coruzzi G, Adami M, 
Haaksma E, and Leurs R, Discovery of quinazolines as histamine H4 receptor inverse 
agonists using a scaffold hopping approach. J.Med.Chem. 51: 7855-7865, 2008. 
 30.  Smits RA, Leurs R, and de Esch IJ, Major advances in the discovery of histamine H(4) 
receptor ligands. Drug Discov.Today, 2009. 
 31.  Strakhova MI, Cuff CA, Manelli AM, Carr TL, Witte DG, Baranowski JL, Vortherms TA, Miller 
TR, Rundell L, McPherson MJ, Adair RM, Brito AA, Bettencourt BM, Yao BB, Wetter JM, 
Marsh KC, Liu H, Cowart MD, Brioni JD, and Esbenshade TA, In vitro and in vivo 
characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory 
properties. Br.J.Pharmacol. 157: 44-54, 2009. 
 32.  Zampeli E and Tiligada E, The role of histamine H4 receptor in immune and inflammatory 
disorders. Br.J.Pharmacol. 157: 24-33, 2009. 
 33.  Huang JF and Thurmond RL, The new biology of histamine receptors. Curr.Allergy Asthma 
Rep. 8: 21-27, 2008. 
 34.  Thurmond RL, Gelfand EW, and Dunford PJ, The role of histamine H1 and H4 receptors in 
allergic inflammation: the search for new antihistamines. Nat.Rev.Drug Discov. 7: 41-53, 2008. 
 35.  Seifert R and Wenzel-Seifert K, Constitutive activity of G-protein-coupled receptors: cause of 
disease and common property of wild-type receptors. Naunyn Schmiedebergs 
Arch.Pharmacol. 366: 381-416, 2002. 
 36.  Milligan G, Bond RA, and Lee M, Inverse agonism: pharmacological curiosity or potential 
therapeutic strategy? Trends Pharmacol.Sci. 16: 10-13, 1995. 
 37.  Bakker RA, Wieland K, Timmerman H, and Leurs R, Constitutive activity of the histamine H(1) 
receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur.J.Pharmacol. 
387: R5-R7, 2000. 
 38.  Leurs R, Church MK, and Taglialatela M, H1-antihistamines: inverse agonism, anti-
inflammatory actions and cardiac effects. Clin.Exp.Allergy 32: 489-498, 2002. 
 39.  Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, 
Ganellin CR, Schwartz JC, and Arrang JM, High constitutive activity of native H3 receptors 
regulates histamine neurons in brain. Nature 408: 860-864, 2000. 
Reference List 
 
 
106 
 40.  Leff P, The two-state model of receptor activation. Trends Pharmacol.Sci. 16: 89-97, 1995. 
 41.  Roland Seifert and Thomas Wieland. G Protein-Coupled Receptors. WILEY-VCH Verlag GmbH 
& Co. KGaA, Weinheim. 3-527-30819-9.  2005.  
 
 42.  Schneider EH and Seifert R, Histamine H(4) receptor-RGS fusion proteins expressed in Sf9 
insect cells: A sensitive and reliable approach for the functional characterization of histamine 
H(4) receptor ligands. Biochem.Pharmacol., 2009. 
 43.  Dy M and Schneider E, Histamine-cytokine connection in immunity and hematopoiesis. 
Cytokine Growth Factor Rev. 15: 393-410, 2004. 
 44.  Zhang M, Thurmond RL, and Dunford PJ, The histamine H(4) receptor: a novel modulator of 
inflammatory and immune disorders. Pharmacol.Ther. 113: 594-606, 2007. 
 45.  Zhang M, Venable JD, and Thurmond RL, The histamine H4 receptor in autoimmune disease. 
Expert.Opin.Investig.Drugs 15: 1443-1452, 2006. 
 46.  Shahid M, Walker GB, Zorn SH, and Wong EH, Asenapine: a novel psychopharmacologic 
agent with a unique human receptor signature. J.Psychopharmacol. 23: 65-73, 2009. 
 47.  Triggiani M, Petraroli A, Loffredo S, Frattini A, Granata F, Morabito P, Staiano RI, Secondo A, 
Annunziato L, and Marone G, Differentiation of monocytes into macrophages induces the 
upregulation of histamine H1 receptor. J.Allergy Clin.Immunol. 119: 472-481, 2007. 
 48.  Dijkstra D, Leurs R, Chazot P, Shenton FC, Stark H, Werfel T, and Gutzmer R, Histamine 
downregulates monocyte CCL2 production through the histamine H4 receptor. J.Allergy 
Clin.Immunol. 120: 300-307, 2007. 
 49.  Damaj BB, Becerra CB, Esber HJ, Wen Y, and Maghazachi AA, Functional expression of H4 
histamine receptor in human natural killer cells, monocytes, and dendritic cells. J.Immunol. 
179: 7907-7915, 2007. 
 50.  Takahashi HK, Morichika T, Iwagaki H, Tamura R, Kubo S, Yoshino T, Mori S, Akagi T, 
Tanaka N, and Nishibori M, Histamine downregulates CD14 expression via H2 receptors on 
human monocytes. Clin.Immunol. 108: 274-281, 2003. 
 51.  Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, and Wilder RL, 
Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. 
J.Immunol. 161: 2586-2593, 1998. 
 52.  van der Pouw Kraan TC, Snijders A, Boeije LC, de Groot ER, Alewijnse AE, Leurs R, and 
Aarden LA, Histamine inhibits the production of interleukin-12 through interaction with H2 
receptors. J.Clin.Invest 102: 1866-1873, 1998. 
 53.  Dohlsten M, Kalland T, Sjogren HO, and Carlsson R, Histamine inhibits interleukin 1 
production by lipopolysaccharide-stimulated human peripheral blood monocytes. 
Scand.J.Immunol. 27: 527-532, 1988. 
 54.  Takahashi HK, Iwagaki H, Mori S, Yoshino T, Tanaka N, and Nishibori M, Histamine inhibits 
lipopolysaccharide-induced interleukin (IL)-18 production in human monocytes. Clin.Immunol. 
112: 30-34, 2004. 
Reference List 
 
 
107 
 55.  Marone G, Gentile M, Petraroli A, De Rosa N, and Triggiani M, Histamine-induced activation 
of human lung macrophages. Int.Arch.Allergy Immunol. 124: 249-252, 2001. 
 56.  Triggiani M, Gentile M, Secondo A, Granata F, Oriente A, Taglialatela M, Annunziato L, and 
Marone G, Histamine induces exocytosis and IL-6 production from human lung macrophages 
through interaction with H1 receptors. J.Immunol. 166: 4083-4091, 2001. 
 57.  Hotermans G, Bury T, and Radermecker MF, Effect of histamine on tumor necrosis factor 
production by human monocytes. Int.Arch.Allergy Appl.Immunol. 95: 278-281, 1991. 
 58.  Azuma Y, Shinohara M, Wang PL, Hidaka A, and Ohura K, Histamine inhibits chemotaxis, 
phagocytosis, superoxide anion production, and the production of TNFalpha and IL-12 by 
macrophages via H2-receptors. Int.Immunopharmacol. 1: 1867-1875, 2001. 
 59.  Laszlo V, Rothe G, Hegyesi H, Szeberenyi JB, Orso E, Schmitz G, and Falus A, Increased 
histidine decarboxylase expression during in vitro monocyte maturation; a possible role of 
endogenously synthesised histamine in monocyte/macrophage differentiation. Inflamm.Res. 
50: 428-434, 2001. 
 60.  Handley SA, Dube PH, and Miller VL, Histamine signaling through the H(2) receptor in the 
Peyer's patch is important for controlling Yersinia enterocolitica infection. 
Proc.Natl.Acad.Sci.U.S.A 103: 9268-9273, 2006. 
 61.  Higuchi S, Tanimoto A, Arima N, Xu H, Murata Y, Hamada T, Makishima K, and Sasaguri Y, 
Effects of histamine and interleukin-4 synthesized in arterial intima on phagocytosis by 
monocytes/macrophages in relation to atherosclerosis. FEBS Lett. 505: 217-222, 2001. 
 62.  Sasaguri Y and Tanimoto A, Role of macrophage-derived histamine in atherosclerosis-- 
chronic participation in the inflammatory response --. J.Atheroscler.Thromb. 11: 122-130, 
2004. 
 63.  Mazzoni A, Young HA, Spitzer JH, Visintin A, and Segal DM, Histamine regulates cytokine 
production in maturing dendritic cells, resulting in altered T cell polarization. J.Clin.Invest 108: 
1865-1873, 2001. 
 64.  Gutzmer R, Diestel C, Mommert S, Kother B, Stark H, Wittmann M, and Werfel T, Histamine 
H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human 
monocyte-derived dendritic cells. J.Immunol. 174: 5224-5232, 2005. 
 65.  Amaral MM, Davio C, Ceballos A, Salamone G, Canones C, Geffner J, and Vermeulen M, 
Histamine improves antigen uptake and cross-presentation by dendritic cells. J.Immunol. 179: 
3425-3433, 2007. 
 66.  Baumer W, Wendorff S, Gutzmer R, Werfel T, Dijkstra D, Chazot P, Stark H, and Kietzmann 
M, Histamine H4 receptors modulate dendritic cell migration through skin--immunomodulatory 
role of histamine. Allergy 63: 1387-1394, 2008. 
 67.  Caron G, Delneste Y, Roelandts E, Duez C, Bonnefoy JY, Pestel J, and Jeannin P, Histamine 
polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J.Immunol. 167: 
3682-3686, 2001. 
 68.  Krouwels FH, Hol BE, Lutter R, Bruinier B, Bast A, Jansen HM, and Out TA, Histamine affects 
interleukin-4, interleukin-5, and interferon-gamma production by human T cell clones from the 
airways and blood. Am.J.Respir.Cell Mol.Biol. 18: 721-730, 1998. 
Reference List 
 
 
108 
 69.  Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, and Thurmond RL, The 
histamine H4 receptor mediates allergic airway inflammation by regulating the activation of 
CD4+ T cells. J.Immunol. 176: 7062-7070, 2006. 
 70.  Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, and Bacon KB, Histamine h(4) 
and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T 
cells. J.Pharmacol.Exp.Ther. 303: 300-307, 2002. 
 71.  Bryce PJ, Mathias CB, Harrison KL, Watanabe T, Geha RS, and Oettgen HC, The H1 
histamine receptor regulates allergic lung responses. J.Clin.Invest 116: 1624-1632, 2006. 
 72.  Morgan RK, McAllister B, Cross L, Green DS, Kornfeld H, Center DM, and Cruikshank WW, 
Histamine 4 receptor activation induces recruitment of FoxP3+ T cells and inhibits allergic 
asthma in a murine model. J.Immunol. 178: 8081-8089, 2007. 
 73.  Hofstra CL, Desai PJ, Thurmond RL, and Fung-Leung WP, Histamine H4 receptor mediates 
chemotaxis and calcium mobilization of mast cells. J.Pharmacol.Exp.Ther. 305: 1212-1221, 
2003. 
 74.  Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, Karlsson L, and Fung-Leung WP, 
Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion 
molecule upregulation. Br.J.Pharmacol. 142: 161-171, 2004. 
 75.  Buckland KF, Williams TJ, and Conroy DM, Histamine induces cytoskeletal changes in human 
eosinophils via the H(4) receptor. Br.J.Pharmacol. 140: 1117-1127, 2003. 
 76.  Barnard R, Barnard A, Salmon G, Liu W, and Sreckovic S, Histamine-induced actin 
polymerization in human eosinophils: an imaging approach for histamine H4 receptor. 
Cytometry A 73: 299-304, 2008. 
 77.  Wadee AA, Anderson R, and Sher R, In vitro effects of histamine on eosinophil migration. 
Int.Arch.Allergy Appl.Immunol. 63: 322-329, 1980. 
 78.  Clark RA, Sandler JA, Gallin JI, and Kaplan AP, Histamine modulation of eosinophil migration. 
J.Immunol. 118: 137-145, 1977. 
 79.  Masini E, Ragazzo E, Vinci MC, Nistri S, Cinci L, Mastroianni R, Thurmond RL, and Salvemini 
D, A selective H4R antagonist prevents antigen-induced asthma-like reaction and airway 
inflammation in guinea pigs. Inflamm.Res. 58 Suppl 1: 9-10, 2009. 
 80.  Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, and Thurmond RL, Histamine H4 
receptor antagonists are superior to traditional antihistamines in the attenuation of 
experimental pruritus. J.Allergy Clin.Immunol. 119: 176-183, 2007. 
 81.  Rossbach K, Wendorff S, Sander K, Stark H, Gutzmer R, Werfel T, Kietzmann M, and Baumer 
W, Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not 
inflammation. Exp.Dermatol. 18: 57-63, 2009. 
 82.  Coruzzi G, Adami M, Guaita E, de Esch IJ, and Leurs R, Antiinflammatory and antinociceptive 
effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat 
model of carrageenan-induced acute inflammation. Eur.J.Pharmacol. 563: 240-244, 2007. 
 83.  Takahashi Y, Kagawa Y, Izawa K, Ono R, Akagi M, and Kamei C, Effect of histamine H4 
receptor antagonist on allergic rhinitis in mice. Int.Immunopharmacol. 9: 734-738, 2009. 
Reference List 
 
 
109 
 84.  Nakano Y, Takahashi Y, Ono R, Kurata Y, Kagawa Y, and Kamei C, Role of histamine H(4) 
receptor in allergic conjunctivitis in mice. Eur.J.Pharmacol. 608: 71-75, 2009. 
 85.  Nathan C, Metchnikoff's Legacy in 2008. Nat.Immunol. 9: 695-698, 2008. 
 86.  Gordon S and Taylor PR, Monocyte and macrophage heterogeneity. Nat.Rev.Immunol. 5: 
953-964, 2005. 
 87.  Geissmann F, Jung S, and Littman DR, Blood monocytes consist of two principal subsets with 
distinct migratory properties. Immunity. 19: 71-82, 2003. 
 88.  Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, 
Weissleder R, and Pittet MJ, The healing myocardium sequentially mobilizes two monocyte 
subsets with divergent and complementary functions. J.Exp.Med. 204: 3037-3047, 2007. 
 89.  Strauss-Ayali D, Conrad SM, and Mosser DM, Monocyte subpopulations and their 
differentiation patterns during infection. J.Leukoc.Biol. 82: 244-252, 2007. 
 90.  Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, and Leenen PJ, 
Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory 
response. J.Immunol. 172: 4410-4417, 2004. 
 91.  Mosser DM and Edwards JP, Exploring the full spectrum of macrophage activation. 
Nat.Rev.Immunol. 8: 958-969, 2008. 
 92.  Bared SM, Buechler C, Boettcher A, Dayoub R, Sigruener A, Grandl M, Rudolph C, Dada A, 
and Schmitz G, Association of ABCA1 with syntaxin 13 and flotillin-1 and enhanced 
phagocytosis in tangier cells. Mol.Biol.Cell 15: 5399-5407, 2004. 
 93.  Lutter D, Ugocsai P, Grandl M, Orso E, Theis F, Lang EW, and Schmitz G, Analyzing M-CSF 
dependent monocyte/macrophage differentiation: expression modes and meta-modes derived 
from an independent component analysis. BMC.Bioinformatics. 9: 100, 2008. 
 94.  Eske K, Breitbach K, Kohler J, Wongprompitak P, and Steinmetz I, Generation of murine bone 
marrow derived macrophages in a standardised serum-free cell culture system. 
J.Immunol.Methods 342: 13-19, 2009. 
 95.  Kono H and Rock KL, How dying cells alert the immune system to danger. Nat.Rev.Immunol. 
8: 279-289, 2008. 
 96.  Chen CJ, Kono H, Golenbock D, Reed G, Akira S, and Rock KL, Identification of a key 
pathway required for the sterile inflammatory response triggered by dying cells. Nat.Med. 13: 
851-856, 2007. 
 97.  Erwig LP and Henson PM, Immunological consequences of apoptotic cell phagocytosis. 
Am.J.Pathol. 171: 2-8, 2007. 
 98.  O'Shea JJ and Murray PJ, Cytokine signaling modules in inflammatory responses. Immunity. 
28: 477-487, 2008. 
 99.  Gordon S, The macrophage: past, present and future. Eur.J.Immunol. 37 Suppl 1: S9-17, 
2007. 
Reference List 
 
 
110 
 100.  Mackaness GB, Cellular immunity and the parasite. Adv.Exp.Med.Biol. 93: 65-73, 1977. 
 101.  Gordon S, Alternative activation of macrophages. Nat.Rev.Immunol. 3: 23-35, 2003. 
 102.  Brandt E, Woerly G, Younes AB, Loiseau S, and Capron M, IL-4 production by human 
polymorphonuclear neutrophils. J.Leukoc.Biol. 68: 125-130, 2000. 
 103.  Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, and Henson PM, Macrophages 
that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through 
autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J.Clin.Invest 101: 890-
898, 1998. 
 104.  Franchimont D, Overview of the actions of glucocorticoids on the immune response: a good 
model to characterize new pathways of immunosuppression for new treatment strategies. 
Ann.N.Y.Acad.Sci. 1024: 124-137, 2004. 
 105.  Mosser DM, The many faces of macrophage activation. J.Leukoc.Biol. 73: 209-212, 2003. 
 106.  Hasko G, Pacher P, Deitch EA, and Vizi ES, Shaping of monocyte and macrophage function 
by adenosine receptors. Pharmacol.Ther. 113: 264-275, 2007. 
 107.  Sirois J, Menard G, Moses AS, and Bissonnette EY, Importance of histamine in the cytokine 
network in the lung through H2 and H3 receptors: stimulation of IL-10 production. J.Immunol. 
164: 2964-2970, 2000. 
 108.  Lucas M, Zhang X, Prasanna V, and Mosser DM, ERK activation following macrophage 
FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J.Immunol. 175: 469-
477, 2005. 
 109.  Aderem A and Underhill DM, Mechanisms of phagocytosis in macrophages. 
Annu.Rev.Immunol. 17: 593-623, 1999. 
 110.  Desjardins M and Griffiths G, Phagocytosis: latex leads the way. Curr.Opin.Cell Biol. 15: 498-
503, 2003. 
 111.  Groves E, Dart AE, Covarelli V, and Caron E, Molecular mechanisms of phagocytic uptake in 
mammalian cells. Cell Mol.Life Sci. 65: 1957-1976, 2008. 
 112.  Russell DG, Vanderven BC, Glennie S, Mwandumba H, and Heyderman RS, The 
macrophage marches on its phagosome: dynamic assays of phagosome function. 
Nat.Rev.Immunol. 9: 594-600, 2009. 
 113.  Vachon E, Martin R, Plumb J, Kwok V, Vandivier RW, Glogauer M, Kapus A, Wang X, Chow 
CW, Grinstein S, and Downey GP, CD44 is a phagocytic receptor. Blood 107: 4149-4158, 
2006. 
 114.  Vachon E, Martin R, Kwok V, Cherepanov V, Chow CW, Doerschuk CM, Plumb J, Grinstein S, 
and Downey GP, CD44-mediated phagocytosis induces inside-out activation of complement 
receptor-3 in murine macrophages. Blood 110: 4492-4502, 2007. 
 115.  Foxman EF, Campbell JJ, and Butcher EC, Multistep navigation and the combinatorial control 
of leukocyte chemotaxis. J.Cell Biol. 139: 1349-1360, 1997. 
Reference List 
 
 
111 
 116.  Schall TJ, Bacon K, Camp RD, Kaspari JW, and Goeddel DV, Human macrophage 
inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct 
populations of lymphocytes. J.Exp.Med. 177: 1821-1826, 1993. 
 117.  Jin T, Zhang N, Long Y, Parent CA, and Devreotes PN, Localization of the G protein 
betagamma complex in living cells during chemotaxis. Science 287: 1034-1036, 2000. 
 118.  Thelen M, Dancing to the tune of chemokines. Nat.Immunol. 2: 129-134, 2001. 
 119.  Neptune ER, Iiri T, and Bourne HR, Galphai is not required for chemotaxis mediated by Gi-
coupled receptors. J.Biol.Chem. 274: 2824-2828, 1999. 
 120.  Hwang JI, Fraser ID, Choi S, Qin XF, and Simon MI, Analysis of C5a-mediated chemotaxis by 
lentiviral delivery of small interfering RNA. Proc.Natl.Acad.Sci.U.S.A 101: 488-493, 2004. 
 121.  Heit B, Robbins SM, Downey CM, Guan Z, Colarusso P, Miller BJ, Jirik FR, and Kubes P, 
PTEN functions to 'prioritize' chemotactic cues and prevent 'distraction' in migrating 
neutrophils. Nat.Immunol. 9: 743-752, 2008. 
 122.  Shortman K and Liu YJ, Mouse and human dendritic cell subtypes. Nat.Rev.Immunol. 2: 151-
161, 2002. 
 123.  Shortman K and Caux C, Dendritic cell development: multiple pathways to nature's adjuvants. 
Stem Cells 15: 409-419, 1997. 
 124.  Kamath AT, Pooley J, O'Keeffe MA, Vremec D, Zhan Y, Lew AM, D'Amico A, Wu L, Tough 
DF, and Shortman K, The development, maturation, and turnover rate of mouse spleen 
dendritic cell populations. J.Immunol. 165: 6762-6770, 2000. 
 125.  Shortman K and Naik SH, Steady-state and inflammatory dendritic-cell development. 
Nat.Rev.Immunol. 7: 19-30, 2007. 
 126.  Naderer T and McConville MJ, The Leishmania-macrophage interaction: a metabolic 
perspective. Cell Microbiol. 10: 301-308, 2008. 
 127.  van Zandbergen G, Bollinger A, Wenzel A, Kamhawi S, Voll R, Klinger M, Muller A, Holscher 
C, Herrmann M, Sacks D, Solbach W, and Laskay T, Leishmania disease development 
depends on the presence of apoptotic promastigotes in the virulent inoculum. 
Proc.Natl.Acad.Sci.U.S.A 103: 13837-13842, 2006. 
 128.  van Zandbergen G, Klinger M, Mueller A, Dannenberg S, Gebert A, Solbach W, and Laskay T, 
Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into 
macrophages. J.Immunol. 173: 6521-6525, 2004. 
 129.  Reiner SL and Locksley RM, The regulation of immunity to Leishmania major. 
Annu.Rev.Immunol. 13: 151-177, 1995. 
 130.  Stenger S, Thuring H, Rollinghoff M, and Bogdan C, Tissue expression of inducible nitric oxide 
synthase is closely associated with resistance to Leishmania major. J.Exp.Med. 180: 783-793, 
1994. 
 131.  Weiss DS, Raupach B, Takeda K, Akira S, and Zychlinsky A, Toll-like receptors are temporally 
involved in host defense. J.Immunol. 172: 4463-4469, 2004. 
Reference List 
 
 
112 
 132.  Rehli M, Sulzbacher S, Pape S, Ravasi T, Wells CA, Heinz S, Sollner L, El Chartouni C, 
Krause SW, Steingrimsson E, Hume DA, and Andreesen R, Transcription factor Tfec 
contributes to the IL-4-inducible expression of a small group of genes in mouse macrophages 
including the granulocyte colony-stimulating factor receptor. J.Immunol. 174: 7111-7122, 
2005. 
 133.  Stockinger S, Kastner R, Kernbauer E, Pilz A, Westermayer S, Reutterer B, Soulat D, Stengl 
G, Vogl C, Frenz T, Waibler Z, Taniguchi T, Rulicke T, Kalinke U, Muller M, and Decker T, 
Characterization of the interferon-producing cell in mice infected with Listeria monocytogenes. 
PLoS.Pathog. 5: e1000355, 2009. 
 134.  Bookout AL and Mangelsdorf DJ, Quantitative real-time PCR protocol for analysis of nuclear 
receptor signaling pathways. Nucl.Recept.Signal. 1: e012, 2003. 
 135.  Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, and Williams RO, Blockade of 
tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway 
for Th1 and Th17 cells. J.Exp.Med. 205: 2491-2497, 2008. 
 136.  Falk W, Tomisawa S, Klimetzek V, and Meltzer MS, Chemotactic activity of bone marrow-
derived macrophages changes with time in culture. Infect.Immun. 33: 629-631, 1981. 
 137.  Song DH, Kang JH, Lee GS, Jeung EB, and Yang MP, Upregulation of tumor necrosis factor-
alpha expression by trans10-cis12 conjugated linoleic acid enhances phagocytosis of RAW 
macrophages via a peroxisome proliferator-activated receptor gamma-dependent pathway. 
Cytokine 37: 227-235, 2007. 
 138.  Pavlinkova G, Yanagawa Y, Kikuchi K, Iwabuchi K, and Onoe K, Effects of histamine on 
functional maturation of dendritic cells. Immunobiology 207: 315-325, 2003. 
 139.  Idzko M, la Sala A, Ferrari D, Panther E, Herouy Y, Dichmann S, Mockenhaupt M, Di Virgilio 
F, Girolomoni G, and Norgauer J, Expression and function of histamine receptors in human 
monocyte-derived dendritic cells. J.Allergy Clin.Immunol. 109: 839-846, 2002. 
 140.  Szeberenyi JB, Pallinger E, Zsinko M, Pos Z, Rothe G, Orso E, Szeberenyi S, Schmitz G, 
Falus A, and Laszlo V, Inhibition of effects of endogenously synthesized histamine disturbs in 
vitro human dendritic cell differentiation. Immunol.Lett. 76: 175-182, 2001. 
 141.  Szeberenyi JB, Laszlo V, Pallinger E, Orso E, Rothe G, Schmitz G, and Falus A, Intracellular 
histamine content increases during in vitro dendritic cell differentiation. Inflamm.Res. 50 Suppl 
2: S112-S113, 2001. 
 142.  Morse KL, Behan J, Laz TM, West RE, Jr., Greenfeder SA, Anthes JC, Umland S, Wan Y, 
Hipkin RW, Gonsiorek W, Shin N, Gustafson EL, Qiao X, Wang S, Hedrick JA, Greene J, 
Bayne M, and Monsma FJ, Jr., Cloning and characterization of a novel human histamine 
receptor. J.Pharmacol.Exp.Ther. 296: 1058-1066, 2001. 
 143.  Coge F, Guenin SP, Rique H, Boutin JA, and Galizzi JP, Structure and expression of the 
human histamine H4-receptor gene. Biochem.Biophys.Res.Commun. 284: 301-309, 2001. 
 144.  Aoi R, Nakashima I, Kitamura Y, Asai H, and Nakano K, Histamine synthesis by mouse T 
lymphocytes through induced histidine decarboxylase. Immunology 66: 219-223, 1989. 
 145.  Fadok VA, Savill JS, Haslett C, Bratton DL, Doherty DE, Campbell PA, and Henson PM, 
Different populations of macrophages use either the vitronectin receptor or the 
Reference List 
 
 
113 
phosphatidylserine receptor to recognize and remove apoptotic cells. J.Immunol. 149: 4029-
4035, 1992. 
 146.  Current Protocols In Immunology. Supplement 11 CPI. 2006.  John Wiley & Sons, Inc.  
 
 147.  Clark RA, Gallin JI, and Kaplan AP, The selective eosinophil chemotactic activity of histamine. 
J.Exp.Med. 142: 1462-1476, 1975. 
 148.  Faith A, Richards DF, Verhoef A, Lamb JR, Lee TH, and Hawrylowicz CM, Impaired secretion 
of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear 
expression of NF-AT2 and jun B: relevance to immunotherapy. Clin.Exp.Allergy 33: 1209-
1215, 2003. 
 149.  Nakamura Y and Hoshino M, TH2 cytokines and associated transcription factors as 
therapeutic targets in asthma. Curr.Drug Targets.Inflamm.Allergy 4: 267-270, 2005. 
 150.  Hartenstein B, Teurich S, Hess J, Schenkel J, Schorpp-Kistner M, and Angel P, Th2 cell-
specific cytokine expression and allergen-induced airway inflammation depend on JunB. 
EMBO J. 21: 6321-6329, 2002. 
 151.  Hu X, Chen J, Wang L, and Ivashkiv LB, Crosstalk among Jak-STAT, Toll-like receptor, and 
ITAM-dependent pathways in macrophage activation. J.Leukoc.Biol. 82: 237-243, 2007. 
 152.  Wagner EF and Eferl R, Fos/AP-1 proteins in bone and the immune system. Immunol.Rev. 
208: 126-140, 2005. 
 153.  Nakayama T, Kato Y, Hieshima K, Nagakubo D, Kunori Y, Fujisawa T, and Yoshie O, Liver-
expressed chemokine/CC chemokine ligand 16 attracts eosinophils by interacting with 
histamine H4 receptor. J.Immunol. 173: 2078-2083, 2004. 
 154.  Schneider E, Rolli-Derkinderen M, Arock M, and Dy M, Trends in histamine research: new 
functions during immune responses and hematopoiesis. Trends Immunol. 23: 255-263, 2002. 
 155.  Laszlo V, Stohr J, Hegyesi H, Rothe G, Orso E, Falus A, and Schmitz G, Increase of histidine 
decarboxylase in human monocytes during macrophage colony stimulating factor induced in 
vitro phagocytic differentiation. Inflamm.Res. 48 Suppl 1: S85-S86, 1999. 
 156.  Gupta A and Devi LA, The use of receptor-specific antibodies to study G-protein-coupled 
receptors. Mt.Sinai J.Med. 73: 673-681, 2006. 
 157.  Michel MC, Wieland T, and Tsujimoto G, How reliable are G-protein-coupled receptor 
antibodies? Naunyn Schmiedebergs Arch.Pharmacol. 379: 385-388, 2009. 
 
 
 
